var title_f36_59_37808="Diclofenac: Pediatric drug information";
var content_f36_59_37808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diclofenac: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/1/32787?source=see_link\">",
"       Diclofenac (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/52/31560?source=see_link\">",
"       Diclofenac (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/43/1720?source=see_link\">",
"       Diclofenac (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13226 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37808=[""].join("\n");
var outline_f36_59_37808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/1/32787?source=related_link\">",
"      Diclofenac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/52/31560?source=related_link\">",
"      Diclofenac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/43/1720?source=related_link\">",
"      Diclofenac (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_59_37809="Kidney transplant PI";
var content_f36_59_37809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kidney transplant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows a person who has had a kidney transplant. The new kidney is put in the lower part of the belly. Its ureter (the tube that carries urine from the kidney to the bladder) is connected to the person's bladder. In many cases, the diseased kidneys are left in place.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Treatment Methods for Kidney Failure: Transplantation. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Available at:",
"     <a href=\"file://kidney.niddk.nih.gov/kudiseases/pubs/transplant\" target=\"_blank\">",
"      file://kidney.niddk.nih.gov/kudiseases/pubs/transplant",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37809=[""].join("\n");
var outline_f36_59_37809=null;
var title_f36_59_37810="Prenatal ultrasound image of allantoic cyst and patent urachus";
var content_f36_59_37810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of allantoic cyst and patent urachus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the clear communication between the bladder (B) and the cyst (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37810=[""].join("\n");
var outline_f36_59_37810=null;
var title_f36_59_37811="Artificial saliva: Drug information";
var content_f36_59_37811=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Artificial saliva: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/46/32483?source=see_link\">",
"    see \"Artificial saliva: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aquoral&trade;;",
"     </li>",
"     <li>",
"      Biotene&reg; Moisturizing Mouth Spray [OTC];",
"     </li>",
"     <li>",
"      Biotene&reg; Oral Balance&reg; [OTC];",
"     </li>",
"     <li>",
"      Caphosol&reg;;",
"     </li>",
"     <li>",
"      Entertainer's Secret&reg; [OTC];",
"     </li>",
"     <li>",
"      Moi-Stir&reg; [OTC];",
"     </li>",
"     <li>",
"      Mouth Kote&reg; [OTC];",
"     </li>",
"     <li>",
"      NeutraSal&reg;;",
"     </li>",
"     <li>",
"      Numoisyn&trade;;",
"     </li>",
"     <li>",
"      Oasis&reg;;",
"     </li>",
"     <li>",
"      SalivaSure&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mucositis (due to high-dose chemotherapy or radiation therapy):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Caphosol&reg;, NeutraSal&reg;: Swish and spit 4-10 doses daily (use for the duration of chemo- or radiation therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Xerostomia:",
"     </b>",
"     Oral: Use as needed, or product-specific dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Aquoral&trade;: 2 sprays 3-4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Biotene&reg; Oral Balance&reg; gel: Apply one-half inch length onto tongue and spread evenly; repeat as often as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Caphosol&reg;, NeutraSal&reg;: Swish and spit 2-10 doses daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Entertainer's Secret&reg;: Spray as often as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mouth Kote&reg; spray: Spray 3-5 times, swish for 8-10 seconds, then spit or swallow; use as often as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Numoisyn&trade; liquid: Use 2 mL as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Numoisyn&trade; lozenges: Dissolve 1 lozenge slowly; maximum 16 lozenges daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oasis&reg; mouthwash: Rinse mouth with ~30 mL twice daily or as needed; do not swallow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oasis&reg; spray: 1-2 sprays as needed; maximum 60 sprays daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SalivaSure&trade;: Dissolve 1 lozenge slowly as needed; for severe symptoms, 1 lozenge per hour is recommended",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biotene&reg; Oral Balance&reg;: Water, starch, sunflower oil, propylene glycol, xylitol, glycerine, purified milk extract (45 mL) [sugar-free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Numoisyn&trade;: Water, sorbitol, linseed extract,",
"     <i>",
"      Chondrus crispus",
"     </i>",
"     , methylparaben, sodium benzoate, potassium sorbate, dipotassium phosphate, propylparaben (300 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Numoisyn&trade;: Sorbitol 0.3 g/lozenge, polyethylene glycol, malic acid, sodium citrate, calcium phosphate dibasic, hydrogenated cottonseed oil, citric acid, magnesium stearate, silicon dioxide (100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SalivaSure&trade;: Xylitol, citric acid, apple acid, sodium citrate dihydrate, sodium carboxymethylcellulose, dibasic calcium phosphate, silica colloidal, magnesium stearate, stearic acid (90s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for reconstitution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeutraSal&reg;: Sodium, phosphates, calcium, chloride, bicarbonate, silicon dioxide (30s, 120s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caphosol&reg;: Dibasic sodium phosphate 0.032%, monobasic sodium phosphate 0.009%, calcium chloride 0.052%, sodium chloride 0.569%, purified water (30 mL) [packaged in two 15 mL ampuls when mixed together provide one 30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entertainer's Secret&reg;: Sodium carboxymethylcellulose, aloe vera gel, glycerin (60 mL) [ethanol free; honey-apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [mouthwash/gargle]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oasis&reg;: Water, glycerin, sorbitol, poloxamer 338, PEG-60, hydrogenated castor oil, copovidone, sodium benzoate, carboxymethylcellulose (473 mL) [ethanol free, sugar free; mild mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aquoral&trade;: Oxidized glycerol triesters and silicon dioxide (40 mL) [contains aspartame; delivers 400 sprays, citrus flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biotene&reg; Moisturizing Mouth Spray: Water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase (45 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moi-Stir&reg;: Water, sorbitol, sodium carboxymethylcellulose, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mouth Kote&reg;: Water, xylitol, sorbitol, yerba santa, citric acid, ascorbic acid, sodium saccharin, sodium benzoate (5 mL, 60 mL, 240 mL) [ethanol free, sugar free; lemon-lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oasis&reg;: Glycerin, cetylpyridinium, copovidone (30 mL) [ethanol free, sugar free; contains sodium benzoate; delivers ~150 sprays, mild mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5445623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Biotene&reg; Oral Balance&reg; gel: Apply on tongue and spread evenly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Biotene&reg; spray: Spray directly into mouth; spray is safe to swallow.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caphosol&reg;: Swish mixed solution thoroughly with",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of mixture (15 mL) for 1 minute and spit; repeat. Avoid eating or drinking for at least 15 minutes after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Entertainer's Secret&reg;: Tilt head back and spray into throat or nostril while inhaling sharply.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mouth Kote&reg; spray: Spray into mouth and swirl for 8-10 seconds; spray may be swallowed or spit out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NeutraSal&reg;: For each dose, swish",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the prepared solution around the mouth for 1 minute and spit out; repeat with the remaining solution. Avoid eating or drinking for at least 15 minutes after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Numoisyn&trade; liquid: Rinse in mouth before swallowing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Numoisyn&trade; lozenges: Dissolve slowly in mouth; move lozenge around mouth for optimal effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oasis&reg; mouthwash: Rinse for 30 seconds.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oasis&reg; spray: Spray into mouth holding bottle upright; do not rinse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SalivaSure&reg; lozenges: Allow lozenge to move around and slowly dissolve in mouth.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F219820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of dry mouth and throat in xerostomia or hyposalivation; adjunct to standard oral care in relief of symptoms associated with chemotherapy or radiation therapy-induced mucositis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14944305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Altered speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abnormal taste, digestive problems (minor), dysphagia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14944303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Numoisyn&trade; liquid: Hypersensitivity to saliva substitute or any component of the formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Numoisyn&trade; lozenges: Fructose intolerance",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5445622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Caphosol&reg;: Contains sodium 75 mg/30 mL dose",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Moi-Stir&reg;: Contains sodium: 6.47 mEq/120 mL, potassium: 1.93 mEq/120 mL, magnesium: 0.128 mEq/120 mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5445636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protein or electrolyte mixtures which restore/replace saliva, lubricate, moisten, clean, and/or provide a coating on oral mucosa",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Furness S, Worthington HV, Bryan G, et al, &ldquo;Interventions for the Management of Dry Mouth: Topical Therapies,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2011, (12):CD008934.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/59/37811/abstract-text/22161442/pubmed\" id=\"22161442\" target=\"_blank\">",
"        22161442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Narhi TO, Meurman JH, and Ainamo A, &ldquo;Xerostomia and Hyposalivation: Causes, Consequences and Treatment in the Elderly,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1999, 15(2):103-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/59/37811/abstract-text/10495070/pubmed\" id=\"10495070\" target=\"_blank\">",
"        10495070",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Papas AS, Clark RE, Martuscelli G, et al, &ldquo;A Prospective, Randomized Trial for the Prevention of Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2003, 31(8): 705-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/59/37811/abstract-text/12692611/pubmed\" id=\"12692611\" target=\"_blank\">",
"        12692611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scully C and Epstein JB, &ldquo; Oral Health Care for the Cancer Patient,&rdquo;",
"      <i>",
"       Oral Oncology",
"      </i>",
"      , 1996, 32(5): 281-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/59/37811/abstract-text/8944831/pubmed\" id=\"8944831\" target=\"_blank\">",
"        8944831",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sweeney MP and Bagg J, &ldquo;The Mouth and Palliative Care,&rdquo;",
"      <i>",
"       Am J Palliat Care",
"      </i>",
"      , 2000, 17(2):118-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/59/37811/abstract-text/11406956/pubmed\" id=\"11406956\" target=\"_blank\">",
"        11406956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8793 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37811=[""].join("\n");
var outline_f36_59_37811=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219823\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219828\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219824\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219825\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219819\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219813\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5445623\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219820\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944305\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944303\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300024\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222850\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5445622\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5445636\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8793\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8793|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/46/32483?source=related_link\">",
"      Artificial saliva: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_59_37812="Renal disease in patients with rheumatoid arthritis";
var content_f36_59_37812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal disease in patients with rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37812/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37812/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37812/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37812/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37812/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37812/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37812/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/59/37812/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of renal disorders can occur in patients with rheumatoid arthritis (RA), due to the underlying disease, to drugs used to treat the inflammatory process, and to concurrent renal disease unrelated to RA, which is more likely in elderly patients with significant comorbid conditions.",
"   </p>",
"   <p>",
"    The most common disorders associated with RA are membranous nephropathy, secondary amyloidosis, a focal, mesangial proliferative glomerulonephritis, rheumatoid vasculitis, and analgesic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Other disorders, such as IgA nephropathy and minimal change disease have also been reported in patients with RA, although this may represent coincidental disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of chronic kidney disease (CKD) in patients with RA has varied between 5 and 50 percent in different series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/3\">",
"     3",
"    </a>",
"    ]. In the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    And Renal Insufficiency (MATRIX) study of 129 patients, 20 percent of patients had an estimated glomerular filtration rate (eGFR) of 60 to 89",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, and 15 percent had an eGFR of 30 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/4\">",
"     4",
"    </a>",
"    ]. CKD may be due to renal diseases associated with RA, which are discussed below, or to concurrent renal disease.",
"   </p>",
"   <p>",
"    The formulas used to calculate the eGFR (Cockcroft-Gault and MDRD) contain the serum creatinine, which must be stable, and factors that affect muscle mass (lean body weight, age, gender, and race) and therefore affect the serum creatinine independent of GFR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history (such as the use of gold or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    ) and timing of the onset can usually help to distinguish among the different causes of renal disease in patients with RA. As an example, only patients with chronic active arthritis are at risk for secondary amyloidosis, although membranous nephropathy can also occur in this setting. In contrast, membranous nephropathy is much more likely when proteinuria develops after a period of quiescent disease that is frequently drug-induced.",
"   </p>",
"   <p>",
"    A careful urinalysis is another factor that can often establish the type of disease that is present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membranous nephropathy and secondary amyloidosis are noninflammatory conditions that are typically associated with moderate to heavy proteinuria, a bland urine sediment, and a relatively normal plasma creatinine concentration.",
"     </li>",
"     <li>",
"      Focal proliferative glomerulonephritis and rheumatoid vasculitis generally cause an active urine sediment (red cells, red cell and other cellular and granular casts).",
"     </li>",
"     <li>",
"      Analgesic nephropathy is associated with a bland urine sediment, possible episodes of flank pain due to passage of sloughed papillae.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these clinicopathologic correlations are not absolute and do not preclude the need for renal biopsy in selected cases to establish a specific diagnosis. In one study, for example, three of 19 patients with membranous nephropathy and three of 33 patients with amyloidosis (all three patients had amyloid deposits limited to the renal vessels) presented only with isolated hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MEMBRANOUS NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy in RA is most often induced by therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    or gold. Because these drugs are now rarely used in RA, membranous nephropathy is observed less often than in the past.",
"   </p>",
"   <p>",
"    The incidence of membranous nephropathy is estimated to be as high as 1 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    and 1 to 3 percent with parenteral gold (with a lower risk associated with oral gold [",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31476?source=see_link\">",
"     auranofin",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Proteinuria generally develops within the first six to 12 months of therapy, but may take as long as three to four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/7\">",
"     7",
"    </a>",
"    ]. Although membranous nephropathy is classically associated with the nephrotic syndrome, many patients with RA present with nonnephrotic proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discontinuation of the drug leads to resolution of the proteinuria in virtually all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. However, protein excretion may continue to rise for the first one to 12 months (mean two months) after the cessation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/7\">",
"     7",
"    </a>",
"    ]. The mean time to resolution of the proteinuria is nine to twelve months, although two to three years may be required in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. This slow rate of recovery is in part related to the subepithelial location of the immune deposits in this disorder. Deposits at this site are separated from the circulation by the glomerular basement membrane. As a result, there is no access to circulating phagocytic cells, leading to slow clearance of the deposits once the antigenic stimulus has been removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SECONDARY (AA) AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic inflammation in RA may be associated with increased production of the acute phase reactant serum amyloid A (SAA) protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A fragment of SAA protein can be deposited in the tissues, typically leading to the nephrotic syndrome if there is renal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/1\">",
"     1",
"    </a>",
"    ]. As noted above, however, some patients have amyloid deposits limited to the renal vessels, leading to hematuria with little or no proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33000?source=see_link\">",
"     \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older studies estimated that the incidence of secondary (AA) amyloidosis was as high as 5 to 10 percent in chronic RA, although the amyloid deposits are often subclinical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/10\">",
"     10",
"    </a>",
"    ]. Serum amyloid A levels were equally increased in patients with and without clinically evident amyloidosis, suggesting that there may be differences (perhaps genetically mediated) in the subsequent degradation to the amyloidogenic AA protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary amyloidosis is now relatively rare in RA because of more effective means of controlling inflammation. Among patients who develop the disease, control of the inflammatory process with medical therapy can lead to resolution both of the proteinuria and of the tissue deposits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23383?source=see_link\">",
"     \"Treatment of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GLOMERULONEPHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with RA have a proliferative glomerulonephritis. In a study of 110 patients with RA who underwent renal biopsy for clinical renal disease presumably related to RA or its therapy, a mesangial proliferative glomerulonephritis was the most common finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/1\">",
"     1",
"    </a>",
"    ]. Forty patients had this lesion, eight of whom had IgA nephropathy. These patients typically presented with hematuria with or without mild proteinuria. How this lesion might be related to RA is unclear.",
"   </p>",
"   <p>",
"    Glomerulonephritis has been described in five patients with RA undergoing immunoadsorption with a staphylococcal protein A column [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/13\">",
"     13",
"    </a>",
"    ]. All patients recovered after cessation of the use of column plus immunosuppressive agents in five. The underlying pathogenic mechanism is unclear, but activation of multiple inflammatory pathways may contribute. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/566?source=see_link&amp;anchor=H6#H6\">",
"     \"Miscellaneous novel therapies in rheumatoid arthritis\", section on 'Immunoadsorption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also multiple reports of glomerulonephritis associated with anti-tumor necrosis factor alpha therapy in patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. These include proliferative lupus nephritis, pauci-immune crescentic glomerulonephritis, and membranous nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glomerulonephritis associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RHEUMATOID VASCULITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid vasculitis typically occurs in patients with long-standing, joint-destructive RA. The areas of the body involved most commonly by RV are the skin, digits, peripheral nerves, eyes, and heart. The most devastating form is characterized by a medium-sized vasculitis reminiscent of and histologically identical to polyarteritis nodosa. The renal findings are similar to those in other systemic vasculitides. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20697?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\", section on 'Renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANALGESIC NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic interstitial nephritis with papillary necrosis most often occurs in patients treated with combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and phenacetin. New cases of what is called analgesic nephropathy have virtually disappeared in Western countries due to the ban on such combinations. Patients with RA who are treated with aspirin alone for many years typically maintain normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/17\">",
"     17",
"    </a>",
"    ]. However, papillary necrosis can occur in patients treated solely with a nonsteroidal antiinflammatory drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37812/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35335?source=see_link\">",
"     \"Risk factors for and pathogenesis of analgesic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/1\">",
"      Helin HJ, Korpela MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 1995; 38:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/2\">",
"      Nakano M, Ueno M, Nishi S, et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 1998; 50:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/3\">",
"      Karstila K, Korpela M, Sihvonen S, Mustonen J. Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study. Clin Rheumatol 2007; 26:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/4\">",
"      Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008; 47:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/5\">",
"      Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/6\">",
"      Katz WA, Blodgett RC Jr, Pietrusko RG. Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med 1984; 101:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/7\">",
"      Hall CL, Fothergill NJ, Blackwell MM, et al. The natural course of gold nephropathy: long term study of 21 patients. Br Med J (Clin Res Ed) 1987; 295:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/8\">",
"      Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988; 34:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/9\">",
"      Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991; 70:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/10\">",
"      Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med 1980; 302:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/11\">",
"      Wegelius O, Teppo AM, Maury CP. Reduced amyloid-A-degrading activity in serum in amyloidosis associated with rheumatoid arthritis. Br Med J (Clin Res Ed) 1982; 284:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/12\">",
"      Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease. Ann Rheum Dis 1987; 46:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/13\">",
"      Iglesias J, D'Agati VD, Levine JS. Acute glomerulonephritis occurring during immunoadsorption with staphylococcal protein A column (Prosorba). Nephrol Dial Transplant 2004; 19:3155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/14\">",
"      Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol 2004; 62:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/15\">",
"      Mor A, Bingham C 3rd, Barisoni L, et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005; 32:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/16\">",
"      Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/17\">",
"      Emkey RD, Mills JA. Aspirin and analgesic nephropathy. JAMA 1982; 247:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37812/abstract/18\">",
"      Allen RC, Petty RE, Lirenman DS, et al. Renal papillary necrosis in children with chronic arthritis. Am J Dis Child 1986; 140:20.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3116 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37812=[""].join("\n");
var outline_f36_59_37812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MEMBRANOUS NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SECONDARY (AA) AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GLOMERULONEPHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RHEUMATOID VASCULITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANALGESIC NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/566?source=related_link\">",
"      Miscellaneous novel therapies in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35335?source=related_link\">",
"      Risk factors for and pathogenesis of analgesic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23383?source=related_link\">",
"      Treatment of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_59_37813="Methoxsalen (systemic): Drug information";
var content_f36_59_37813=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methoxsalen (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/41/24212?source=see_link\">",
"    see \"Methoxsalen (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8770717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8770721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      8-MOP&reg;;",
"     </li>",
"     <li>",
"      Oxsoralen-Ultra&reg;;",
"     </li>",
"     <li>",
"      Uvadex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8770722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oxsoralen-Ultra&reg;;",
"     </li>",
"     <li>",
"      Oxsoralen&reg; Capsule;",
"     </li>",
"     <li>",
"      Ultramop&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8770782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Psoralen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8770883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Refer to treatment protocols for UVA exposure guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 10-70 mg 1.5-2 hours (Oxsoralen-Ultra&reg;) or 2 hours (8-MOP&reg;) before exposure to UVA light; dose may be repeated 2-3 times per week, based on UVA exposure; doses must be given at least 48 hours apart; dosage is based upon patient's body weight and skin type:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;30 kg: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     30-50 kg: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     51-65 kg: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     66-80 kg: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     81-90 kg: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     91-115 kg: 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;115 kg: 70 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage may be increased (one time) by 10 mg after 15th treatment if minimal or no response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: When 95% psoriasis clearing achieved, may begin 1 treatment every week for at least 2 treatments; followed by 1 treatment every 2 weeks for at least 2 treatments; then every 3 weeks for at least 2 treatments then as needed to maintain response while minimizing UVA exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitiligo:",
"     </b>",
"     Oral (8-MOP&reg;): 20 mg 2-4 hours before exposure to UVA light; dose may be repeated based on erythema and tenderness of skin; do not give on 2 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CTCL:",
"     </b>",
"     Extracorporeal (Uvadex&reg;): Dose is determined by treatment volume; amount of Uvadex&reg; needed for each treatment may be calculated using the following equation: Treatment volume x 0.017 = mL of Uvadex&reg; needed. Inject this amount into the photoactivation bag during the collection cycle using the UVAR&reg; photopheresis system (consult user's guide).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment schedule:",
"     </i>",
"     Two consecutive days every 4 weeks for a minimum of 7 treatment cycles, may accelerate to 2 consecutive days every 2 weeks if skin score worsens (eg, increases from baseline) after assessment during the fourth treatment cycle. If skin score improves by 25% after 4 consecutive weeks of accelerated therapy, may resume regular treatment schedule. Maximum: 20 accelerated therapy cycles.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8770884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8770913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8-MOP&reg;: 10 mg [hard-gelatin capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxsoralen-Ultra&reg;: 10 mg [soft-gelatin capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for extracorporeal administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uvadex&reg;: 20 mcg/mL (10 mL) [contains ethanol 0.05 mL/mL; not for injection]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8770764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9531474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: To reduce nausea, capsules should be administered with food or milk.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8770810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Symptomatic control of severe, recalcitrant disabling psoriasis; repigmentation of idiopathic vitiligo; palliative treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extracorporeal: Palliative treatment of skin manifestations of CTCL",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8770719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methoxsalen soft gelatin capsules (Oxsoralen-Ultra&reg;) may be confused with methoxsalen hard  gelatin capsules (8-MOP&reg;); bioavailability and photosensitization onset differ between the two products.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8770819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hypotension (due to photophoresis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, headache, insomnia, malaise, nervousness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus (10%), blistering (painful), bullae formation, burning, erythema, folliculitis, freckling, hypopigmentation, miliaria, peeling of skin, premature aging, rash, skin cancer, tenderness (cutaneous), urticaria, vesiculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection (due to vascular access for photophoresis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8770815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methoxsalen (psoralens) or any component of the formulation; diseases associated with photosensitivity (eg, albinism, lupus erythematosus, porphyria [cutanea tarda, erythropoietic and variegate], xeroderma pigmentosum); invasive squamous cell cancer; aphakia; melanoma or history of melanoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8770816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burns: Serious burns may occur from ultraviolet radiation or sunlight (even if exposed through glass) if recommended dose and/or exposure schedule is not maintained.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cataracts: Methoxsalen concentrates in the lens; eyes should be shielded from direct and indirect sunlight for 24 hours to prevent possible formation of cataracts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Avoid sun (including sun lamp) exposure for 8 hours after methoxsalen ingestion. Protective clothing, eyewear, and sunscreen (do not apply sunscreen to psoriatic areas) should be used for 24 hours after combined methoxsalen/UVA therapy. Do not use in sunburned patients until they have fully recovered; pre-existing sunburn may obscure evaluation of response; advise patients to avoid sunbathing for 24 hours prior to treatment and for 48 hours after treatment. Use extreme caution in patients who have significant exposure to the sun through their occupation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin cancer: Therapy may lead to increased risk of skin cancer (basal cell, melanoma and squamous cell); this risk may be increased with fair skin or prior exposure to prolonged tar and UVB treatment, ionizing radiation, or arsenic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Basal cell carcinoma: Use with caution in patients with multiple basal cell carcinomas or a history of basal cell carcinoma; observe closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (may not be able to tolerate the heat stress or prolonged standing related to UVA treatment conditions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Methoxsalen undergoes hepatic metabolism; use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitizing agents: Use caution with other (systemic or topical) photosensitizing drugs (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides, anthralin, coal tar preparations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children for CTCL or psoriasis and &lt;12 years of age for vitiligo. The long-term effects of treatment (including potential cataract formation, skin cancer development, and premature skin aging) are unknown in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchange:",
"     <b>",
"      [U.S. Boxed Warning]: Soft-gelatin capsule (Oxsoralen-Ultra&reg;) and hard-gelatin capsule (8-MOP&reg;) are not interchangeable; retitration is required if the formulation is changed.",
"     </b>",
"     Oxsoralen-Ultra&reg; has a greater bioavailability and shorter onset of photosensitization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: CTCL: For use only if inadequate response to other forms of therapy. Used in conjunction with long wave radiation of white blood cells using the UVAR&reg; photopheresis system.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Psoriasis: For use only if inadequate response to other therapies when the diagnosis is biopsy proven. Administer only in conjunction with scheduled controlled doses of long wave ultraviolet (UVA) radiation (combination referred to as PUVA).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Vitiligo: Used in conjunction with controlled doses of long wave ultraviolet radiation or sunlight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced physician with special competence in the diagnosis and treatment of dermatologic diseases.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8770822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP2A6 (strong), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8770823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Strong) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8770847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Methoxsalen serum concentrations may be increased if taken with food. Nausea can occur upon administration. Management: Capsules should be taken with food or milk. Avoid furocoumarin-containing foods (limes, figs, parsley, celery, cloves, lemon, mustard, carrots).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8770811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D (Uvadex&reg;) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8770812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal toxicity has been observed in animal studies. Use during pregnancy is not recommended. Women of childbearing potential should be advised to avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8770814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8770885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To reduce nausea, capsules should be taken with food or milk. Avoid furocoumarin-containing foods (limes, figs, parsley, celery, cloves, lemon, mustard, carrots).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8770915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (8-Mop Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (50): $1770.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Oxsoralen Ultra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (50): $2973.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Uvadex Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mcg/mL (10 mL): $41.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8770902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (baseline and every 6-12 months), liver and renal function tests (baseline and every 6-12 months), antinuclear antibodies (baseline and every 6-12 months); ophthalmic exam (pretreatment and yearly)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Delsoralen (ID);",
"     </li>",
"     <li>",
"      Lukodermine (PK);",
"     </li>",
"     <li>",
"      Meladinina (CR, DO, GT, NI, PA, PY, SV);",
"     </li>",
"     <li>",
"      Meladinine (CL, FR, TH);",
"     </li>",
"     <li>",
"      Melanocyl (IN);",
"     </li>",
"     <li>",
"      Metoxaleno (UY);",
"     </li>",
"     <li>",
"      Mopsalem (CO);",
"     </li>",
"     <li>",
"      Mopsoralen (BE);",
"     </li>",
"     <li>",
"      Oxsoralen (AR, BR, CN, CZ, HK, NO);",
"     </li>",
"     <li>",
"      Sorialen (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8770848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bonds covalently to pyrimidine bases in DNA, inhibits the synthesis of DNA, and suppresses cell division. The augmented sunburn reaction involves excitation of the methoxsalen molecule by radiation in the long-wave ultraviolet light (UVA), resulting in transference of energy to the methoxsalen molecule producing an excited state (&ldquo;triplet electronic state&rdquo;). The molecule, in this &ldquo;triplet state,&rdquo; then reacts with cutaneous DNA.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8770873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Reversibly bound to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Bioavailability increased with soft-gelatin capsules (Oxsoralen-Ultra&reg;) compared to hard-gelatin capsules (8-MOP&reg;); exposure using Uvadex&reg; with the UVAR&reg; photopheresis system is ~200 times less than with oral methoxsalen administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hard-gelatin capsules (8-MOP&reg;): 1.5-6 hours (peak photosensitivity: ~4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Soft-gelatin capsules (Oxsoralen-Ultra&reg;): 0.5-4 hours (peak photosensitivity: 1.5-2 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~95% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Stern RS, &ldquo;Psoralen and Ultraviolet a Light Therapy for Psoriasis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(7):682-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/59/37813/abstract-text/17699818/pubmed\" id=\"17699818\" target=\"_blank\">",
"        17699818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stern RS, Nichols KT and Vateva LH, &ldquo;Malignant Melanoma in Patients Treated for Psoriasis With Methoxsalen (Psoralen) and Ultraviolet A Radiation (PUVA). The PUVA Follow-Up Study,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(15):1041-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/59/37813/abstract-text/9091799/pubmed\" id=\"9091799\" target=\"_blank\">",
"        9091799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9577 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.111-11ACF9297B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37813=[""].join("\n");
var outline_f36_59_37813=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770717\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770721\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770722\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770782\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770883\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770884\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770913\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770764\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9531474\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770810\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770719\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770819\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770815\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770816\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770822\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770823\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770847\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770811\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770812\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770814\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770885\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770915\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770902\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961986\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770848\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770873\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9577\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9577|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/41/24212?source=related_link\">",
"      Methoxsalen (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/19/21811?source=related_link\">",
"      Methoxsalen (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/5/2132?source=related_link\">",
"      Methoxsalen (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_59_37814="Microbiology; pathogenesis; and epidemiology of Rhodococcus equi infections";
var content_f36_59_37814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology; pathogenesis; and epidemiology of Rhodococcus equi infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37814/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37814/contributors\">",
"     Leonard N Slater, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37814/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37814/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37814/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37814/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/59/37814/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 9, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhodococcus equi has been recognized as an animal pathogen since its original isolation as Corynebacterium equi in 1923 from foals with pneumonia. Foals less than six months old are uniquely susceptible to the development of a chronic suppurative bronchopneumonia that can lead to lung and bronchial lymph node abscesses. Ulcerative colitis and mesenteric adenitis may also occur, usually associated with pulmonary infection. In swine, R. equi is commonly isolated from the lymph nodes of animals with submaxillary adenitis. The organism can rarely cause pulmonary and extrapulmonary abscesses, wound infections, and lymphadenitis in other animals, primarily rooting and grazing mammals. However, when hosts other than foals and swine develop R. equi infections, they are frequently immunocompromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rhodococcus equi once rarely produced human infection. The first case was reported in 1967 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/2\">",
"     2",
"    </a>",
"    ], and only 12 additional cases were recorded in the next 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/3\">",
"     3",
"    </a>",
"    ]. While still not commonplace, R. equi has been isolated increasingly, especially as an opportunistic pathogen. Most human infections have been associated with immune system dysfunction, and a dramatic increase has occurred since the recognition of the human immunodeficiency virus (HIV) pandemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/4-13\">",
"     4-13",
"    </a>",
"    ]. Concurrently, increasing recognition of R. equi as a pathogen has led to improved laboratory identification of infections in both immunocompromised and normal humans.",
"   </p>",
"   <p>",
"    The microbiology, pathogenesis, and epidemiology of Rhodococcus equi infections will be reviewed here. The clinical manifestations, diagnosis, treatment, and prevention of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18791?source=see_link\">",
"     \"Clinical features; diagnosis; therapy; and prevention of Rhodococcus equi infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;R. equi was originally named Corynebacterium equi in 1923 based upon its morphologic appearance. Subsequently, the cell wall composition and biochemical reactions were found to be more closely related to nocardia and mycobacteria than corynebacteria; in 1980 the organism was reclassified in the genus Rhodococcus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23991?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22378?source=see_link\">",
"     \"Microbiology and pathogenesis of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Part of the phylogenetic group of nocardioform actinomycetes, Rhodococcus is characterized in part by rod-to-coccus growth cycle variation and the presence of tuberculostearic acid and cell wall mycolic acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/1\">",
"     1",
"    </a>",
"    ]. Little is known about the pathogenic potential of rhodococci other than R. equi. Some have been isolated from granulomatous lesions in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/1\">",
"     1",
"    </a>",
"    ], but reports of disease are rare.",
"   </p>",
"   <p>",
"    R. equi is easily cultivated on ordinary nonselective media when incubated aerobically at 37&ordm;C. Large, smooth, irregular, highly mucoid colonies develop by 48 hours. Although named for its production of red pigment, cultures less than four days old rarely appear pigmented. After four to seven days of incubation, colonies usually develop a delicate salmon pink color, although they may also be nonpigmented or slightly yellow (",
"    <a class=\"graphic graphic_picture graphicRef64676 \" href=\"mobipreview.htm?26/63/27634\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pleomorphism characterizes this gram-positive organism. On solid media and in clinical specimens, it typically appears coccoid, but in liquid media, particularly in young cultures, it forms long rods or short filaments, at times with rudimentary branching [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/1\">",
"     1",
"    </a>",
"    ]. The organisms can be acid fast with the Ziehl-Neelsen stain, but this is not a constant feature and is related to the age of the culture and the growth media. Growth on Lowenstein-Jensen agar, one medium used to isolate mycobacteria, may promote acid-fastness.",
"   </p>",
"   <p>",
"    R. equi is non-fermentive (distinguishing it from pathogenic corynebacteria), gelatinase-negative, catalase positive, usually urease positive, and oxidase negative. So-called equi factors are elaborated that interact with the products of other organisms, including the beta toxin of Staphylococcus aureus, to produce hemolysis. Lipase and phosphatase are produced, but not DNAase, elastase, or protease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/14\">",
"     14",
"    </a>",
"    ]. At least 27 different polysaccharide capsular serotypes have been identified, but no relationship between serotype and virulence has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the modern microbiology laboratory, a commercially available panel of biochemical tests (API Rapid CORYNE&reg;, bioM&eacute;rieux Vitek Inc., Hazelwood, MO) can be employed to easily identify R. equi. This panel should be applied to isolates with the typical colony characteristics and Gram's stain morphology described above. It is crucial for the laboratory to perform these tests in order to recognize the pathogenic potential of such isolates, and not to discount them automatically as contaminants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction of R. equi infection has been studied primarily in the foal, its major natural host, and in murine models. Many of the findings in animals may be applicable to the pathogenesis of human infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Virulence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenic potential of R. equi results from its ability to persist in and destroy macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/1\">",
"     1",
"    </a>",
"    ]. The organism appears to evade killing by interfering with phagosome-lysosome fusion; induction of nonspecific lysosome degranulation may be the means by which infected macrophages and surrounding tissues are destroyed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variation in the virulence of R. equi isolates has been demonstrated in experimentally infected mice and foals; clinical isolates are usually more pathogenic than environmental isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/17\">",
"     17",
"    </a>",
"    ]. However, assays of extracellular enzyme production by clinical and environmental isolates reveal no clear differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/14\">",
"     14",
"    </a>",
"    ]. The ability of different serotypes to resist clearance from the lung and spleen and to evade phagocytosis and intracellular killing by peritoneal macrophages is associated with virulence in murine models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High level virulence in mice and foals has also been associated with the presence of 15 to 17 kDA antigens, the expression of which is dependent upon the presence of 85- and 90-kb plasmids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Three-quarters of pathogenic isolates from humans with the acquired immunodeficiency syndrome (AIDS) have been found to contain these antigens or a 20 kDa one, which requires the presence of 70 to 95 kb plasmids and is associated with intermediate virulence in murine models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/23\">",
"     23",
"    </a>",
"    ]. The 20 kDa antigen has been identified in swine submaxillary gland isolates, suggesting a possible epidemiologic link [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/24\">",
"     24",
"    </a>",
"    ]. However, no virulence antigens have been detected in pathogenic isolates from other immunocompromised hosts such as renal transplant recipients or patients with lymphoproliferative malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defective intracellular processing of R. equi leads to a characteristic histopathologic pattern in clinical specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Granulomatous reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical appearance is a necrotizing granulomatous reaction dominated by macrophages filled with granular cytoplasm that is periodic acid Schiff (PAS) stain-positive and may contain large numbers of gram-positive coccobacillary forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/9\">",
"     9",
"    </a>",
"    ]. Pathologic change elicited by R. equi resembles that of other members of the Corynebacterium-Mycobacterium-Nocardia group, which share lipid-rich cell wall components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Malacoplakia",
"    </span>",
"    &nbsp;&mdash;&nbsp;R. equi pulmonary and extrapulmonary infections of humans also have been associated with an unusual chronic granulomatous inflammation called malacoplakia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/9,25\">",
"     9,25",
"    </a>",
"    ], characterized by aggregates of PAS positive histiocytes containing lamellated iron and calcium inclusions named Michaelis-Gutmann bodies. These structures are believed to result from incomplete intracellular digestion of engulfed bacteria by macrophages. Residual intralysosomal debris acts as a nidus for mineralization and leads to the development of complex lysosomal bodies demonstrable by Prussian blue (iron) and von Kossa (calcium) stains. Malacoplakia most commonly involves the genitourinary tract, but many other sites have been reported, particularly in immunocompromised hosts. This pathologic response is not pathognomonic of R. equi infection since it can be observed in infections caused by coliform bacteria and occasionally mycobacteria, but the association with R. equi is strong.",
"   </p>",
"   <p>",
"    R. equi infection rarely produces a pathologic appearance that resembles Whipple's disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11833?source=see_link\">",
"     \"Whipple's disease\"",
"    </a>",
"    .) An infection mimicking Whipple's disease has been observed in AIDS patients, most commonly due to Mycobacterium avium complex (MAC), but several cases have also been associated with R. equi lung infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/9\">",
"     9",
"    </a>",
"    ]. Analysis of 16S ribosomal RNA sequences has shown that the Whipple's disease bacillus (Tropheryma whipplei) and R. equi are both actinomycetes although only distantly related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/26\">",
"     26",
"    </a>",
"    ]. Histologic features of Whipple's disease parallel those of R. equi enteritis in foals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMMUNE RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some herbivores have asymptomatic carriage of R. equi in their gastrointestinal tracts but do not appear to be susceptible to infection with the organism. Infection in some humans with normal immunologic function may arise from a similar route. Several cases illustrate a potential for the organism to disseminate to regional lymph nodes in immunocompetent individuals and to persist with a possibility of later reactivation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An asymptomatic woman had mesenteric adenitis with R. equi noted incidentally at laparotomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An alcoholic man developed R. equi peritonitis during an episode of hepatic decompensation; the organism was found in mesenteric nodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Manifestations of R. equi infection in immunocompromised humans resemble those in foals. Most knowledge about immune responses to R. equi infection comes from animal research. Both humoral and cell-mediated immunity (CMI) appear important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Humoral immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to R. equi are widespread in the mature horse population. Maternal antibody from colostrum declines to its lowest levels at eight weeks of age in foals; those with low levels are particularly susceptible to naturally-induced R. equi pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/29\">",
"     29",
"    </a>",
"    ]. Antibodies can be induced by subcutaneous or intranasal inoculation of the organism in horses, and plasma from immunized horses dramatically lessens the severity of disease in foals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cell-mediated immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its intracellular location and the propensity for infection to occur in HIV-infected individuals, CMI mechanisms are thought to be a major means of defense against R. equi. Delayed-type hypersensitivity reactions are widespread in horses demonstrating ubiquitous exposure to R. equi. Experimental equine infections can induce such immune responses as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Euthymic mice treated with antibodies to either interferon gamma or tumor necrosis factor- (TNF) alpha had higher colony counts of R. equi in tissues compared to untreated animals in a model where the organism was injected intravenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/32\">",
"     32",
"    </a>",
"    ]. This experiment suggests that both T cell- and macrophage-secreted cytokines play a role in a CMI response.",
"   </p>",
"   <p>",
"    In humans, most R. equi infections have been associated with profound impairment of CMI, predominantly AIDS with CD4 lymphocyte counts below",
"    <span class=\"nowrap\">",
"     200/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/13\">",
"     13",
"    </a>",
"    ]. Other immunocompromised hosts at risk include those with lymphoproliferative malignancies and solid organ transplants, mainly renal allografts. Most immunocompromised hosts without HIV infection who develop R. equi infections also have been taking immunosuppressive therapy, either steroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cytotoxic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Interactions between cell-mediated and humoral immune responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interactions between cell-mediated and humoral immunity have been revealed by in vitro studies of macrophage killing of R. equi. In athymic mice, transfer of spleen cells from mice previously immunized with live bacteria protected against R. equi infection, while passive transfer of immune serum from such mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/33\">",
"     33",
"    </a>",
"    ]. However, in vitro killing by macrophages was enhanced by exposure to supernatants from lymphocyte cultures stimulated with R. equi antigens. Phagosome-lysosome fusion within macrophages was markedly increased with opsonized compared to non-opsonized bacteria. The combination of specific antibody and activated macrophages resulted in complete killing by incubated macrophages in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible expression of this dual role of cell-mediated and humoral immune function may be found in AIDS patients. Despite cellular immunosuppression, some AIDS patients with R. equi pneumonia can develop antibodies to the organism; the magnitude of this antibody response may correlate with a potential for recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;R. equi is a soil organism carried in the gut of many herbivores and widespread in their environment. It has been isolated from 54 percent of soil sites examined in Australia, including 18 of 19 horse farms. However, some isolates were from areas where no animals had grazed within memory. R. equi was isolated from gut contents or dung of all herbivores examined that grazed in those areas, but from none that were penned and unable to graze.",
"   </p>",
"   <p>",
"    On horse farms, progressive environmental contamination with R. equi has been related to the length of time that animals were present. The highest numbers of organisms have been found in the surface soil on horse farms with endemic disease. The number of organisms isolated from the air increased with warmer temperatures and was highest on dry and windy days. The simple nutrient growth requirements of R. equi are met completely by horse manure. Thus, the organism appears to thrive in the interaction between grazing herbivores and their environment.",
"   </p>",
"   <p>",
"    Exposure to soil contaminated with herbivore manure is likely the major route of acquisition for both animal and human infection. Contact with farm animals or manure has been reported in 32 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37814/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. Considering that this epidemiologic information is not often sought or reported, the true percentage may be even higher.",
"   </p>",
"   <p>",
"    The presentation of R. equi infections either as pneumonia or as disease associated with the gastrointestinal tract without pulmonary involvement suggests that humans and animals can acquire infection by either inhalation or ingestion of contaminated material. The former route clearly predominates in humans. Human and animal infection can also be acquired by traumatic inoculation or superinfection of wounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30080612\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rhodococcus equi has been recognized as an animal pathogen since its original isolation in 1923 from foals with pneumonia. R. equi only rarely causes human infections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      R. equi is easily cultivated on ordinary nonselective media when incubated aerobically at 37&ordm;C. Large, smooth, highly mucoid colonies develop by 48 hours. After four to seven days of incubation, colonies usually develop a salmon pink color. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenic potential of R. equi results from its ability to persist within and destroy macrophages. The organism evades killing by interfering with phagosome-lysosome fusion. Nonspecific lysosome degranulation leads to destruction of infected macrophages and the surrounding tissues. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Virulence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical histologic appearance of R. equi infection includes a necrotizing granulomatous reaction dominated by macrophages filled with granular cytoplasm. Periodic acid Schiff (PAS) staining may demonstrate large numbers of gram-positive coccobacillary forms, representative of the organism. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologically, R. equi pulmonary and extrapulmonary infections have been associated with an unusual chronic granulomatous inflammation called &ldquo;malacoplakia&rdquo;, characterized by aggregates of PAS-positive histiocytes containing lamellated iron and calcium inclusions. These structures may result from incomplete intracellular digestion of engulfed bacteria by macrophages. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Malacoplakia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In humans, most R. equi infections have been associated with profound impairment of cell-mediated immunity, as seen in patients with AIDS, lymphoproliferative malignancies, and solid organ transplant recipients taking immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cell-mediated immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      From an epidemiologic viewpoint, R. equi is widespread in the environment, including soil and the gut of many herbivores. It is likely that humans and animals acquire infection by either inhalation or ingestion of contaminated liquids or solids. Human and animal infection can also be acquired by traumatic inoculation or superinfection of wounds. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/1\">",
"      Prescott JF. Rhodococcus equi: an animal and human pathogen. Clin Microbiol Rev 1991; 4:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/2\">",
"      Golub B, Falk G, Spink WW. Lung abscess due to Corynebacterium equi. Report of first human infection. Ann Intern Med 1967; 66:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/3\">",
"      Van Etta LL, Filice GA, Ferguson RM, Gerding DN. Corynebacterium equi: a review of 12 cases of human infection. Rev Infect Dis 1983; 5:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/4\">",
"      Harvey RL, Sunstrum JC. Rhodococcus equi infection in patients with and without human immunodeficiency virus infection. Rev Infect Dis 1991; 13:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/5\">",
"      Emmons W, Reichwein B, Winslow DL. Rhodococcus equi infection in the patient with AIDS: literature review and report of an unusual case. Rev Infect Dis 1991; 13:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/6\">",
"      Lasky JA, Pulkingham N, Powers MA, Durack DT. Rhodococcus equi causing human pulmonary infection: review of 29 cases. South Med J 1991; 84:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/7\">",
"      Drancourt M, Bonnet E, Gallais H, et al. Rhodococcus equi infection in patients with AIDS. J Infect 1992; 24:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/8\">",
"      Verville TD, Huycke MM, Greenfield RA, et al. Rhodococcus equi infections of humans. 12 cases and a review of the literature. Medicine (Baltimore) 1994; 73:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/9\">",
"      Scott MA, Graham BS, Verrall R, et al. Rhodococcus equi--an increasingly recognized opportunistic pathogen. Report of 12 cases and review of 65 cases in the literature. Am J Clin Pathol 1995; 103:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/10\">",
"      Donisi A, Suardi MG, Casari S, et al. Rhodococcus equi infection in HIV-infected patients. AIDS 1996; 10:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/11\">",
"      Arlotti M, Zoboli G, Moscatelli GL, et al. Rhodococcus equi infection in HIV-positive subjects: a retrospective analysis of 24 cases. Scand J Infect Dis 1996; 28:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/12\">",
"      Hsueh PR, Hung CC, Teng LJ, et al. Report of invasive Rhodococcus equi infections in Taiwan, with an emphasis on the emergence of multidrug-resistant strains. Clin Infect Dis 1998; 27:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/13\">",
"      Torres-Tortosa M, Arrizabalaga J, Villanueva JL, et al. Prognosis and clinical evaluation of infection caused by Rhodococcus equi in HIV-infected patients: a multicenter study of 67 cases. Chest 2003; 123:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/14\">",
"      Mutimer MD, Woolcock JB. A note on hydrolytic enzymes of Corynebacterium equi. J Appl Bacteriol 1983; 55:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/15\">",
"      Nakazawa M, Kubo M, Sugimoto C, Isayama Y. Serogrouping of Rhodococcus equi. Microbiol Immunol 1983; 27:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/16\">",
"      Zink MC, Yager JA, Prescott JF, Fernando MA. Electron microscopic investigation of intracellular events after ingestion of Rhodococcus equi by foal alveolar macrophages. Vet Microbiol 1987; 14:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/17\">",
"      Bowles PM, Woolcock JB, Mutimer MD. Experimental infection of mice with Rhodococcus equi: differences in virulence between strains. Vet Microbiol 1987; 14:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/18\">",
"      Nakazawa M, Haritani M, Sugimoto C, Isayama Y. Virulence of Rhodococcus equi for mice. Nihon Juigaku Zasshi 1983; 45:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/19\">",
"      Takai S, Michizoe T, Matsumura K, et al. Correlation of in vitro properties of Rhodococcus (Corynebacterium) equi with virulence for mice. Microbiol Immunol 1985; 29:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/20\">",
"      Takai S, Koike K, Ohbushi S, et al. Identification of 15- to 17-kilodalton antigens associated with virulent Rhodococcus equi. J Clin Microbiol 1991; 29:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/21\">",
"      Takai S, Sekizaki T, Ozawa T, et al. Association between a large plasmid and 15- to 17-kilodalton antigens in virulent Rhodococcus equi. Infect Immun 1991; 59:4056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/22\">",
"      Takai S, Madarame H, Matsumoto C, et al. Pathogenesis of Rhodococcus equi infection in mice: roles of virulence plasmids and granulomagenic activity of bacteria. FEMS Immunol Med Microbiol 1995; 11:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/23\">",
"      Takai S, Imai Y, Fukunaga N, et al. Identification of virulence-associated antigens and plasmids in Rhodococcus equi from patients with AIDS. J Infect Dis 1995; 172:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/24\">",
"      Takai S, Fukunaga N, Ochiai S, et al. Identification of intermediately virulent Rhodococcus equi isolates from pigs. J Clin Microbiol 1996; 34:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/25\">",
"      Scannell KA, Portoni EJ, Finkle HI, Rice M. Pulmonary malacoplakia and Rhodococcus equi infection in a patient with AIDS. Chest 1990; 97:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/26\">",
"      Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 1992; 327:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/27\">",
"      Germain P, Deville J, Remy G, Dropsy G. A propos d'une observation d'infection humaine &agrave; Corynebacterium equi. Med Mal Infect 1975; 5:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/28\">",
"      Peloux Y, Durand JM, Fosse T. P&eacute;ritonite &agrave; Corynebacterium (Rhodococcus) equi chez un cirrhotique. Sem H&ocirc;p Paris 1985; 61:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/29\">",
"      Ardans AA, Hietala SK, Spensley MS, Sansome A. Studies of naturally occurring and experimental Rhodococcus equi (Corynebacterium equi) pneumonia in foals. Proc Am Assoc Equine Pract 1986; 32:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/30\">",
"      Martens RJ, Martens JG, Fiske RA, Hietala SK. Rhodococcus equi foal pneumonia: protective effects of immune plasma in experimentally infected foals. Equine Vet J 1989; 21:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/31\">",
"      Ellenberger MA, Kaeberle ML, Roth JA. Equine cell-mediated immune response to Rhodococcus (Corynebacterium) equi. Am J Vet Res 1984; 45:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/32\">",
"      Nordmann P, Ronco E, Guenounou M. Involvement of interferon-gamma and tumor necrosis factor-alpha in host defense against Rhodococcus equi. J Infect Dis 1993; 167:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/33\">",
"      Nordmann P, Ronco E, Nauciel C. Role of T-lymphocyte subsets in Rhodococcus equi infection. Infect Immun 1992; 60:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/34\">",
"      Hietala SK, Ardans AA. Interaction of Rhodococcus equi with phagocytic cells from R. equi-exposed and non-exposed foals. Vet Microbiol 1987; 14:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37814/abstract/35\">",
"      Vullo V, Mastroianni CM, Lichtner M, et al. Serologic responses to Rhodococcus equi in individuals with and without human immunodeficiency virus infection. Eur J Clin Microbiol Infect Dis 1996; 15:588.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5511 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37814=[""].join("\n");
var outline_f36_59_37814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30080612\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Virulence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Granulomatous reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Malacoplakia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMMUNE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Humoral immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cell-mediated immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Interactions between cell-mediated and humoral immune responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30080612\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5511\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5511|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/63/27634\" title=\"picture 1\">",
"      Pink colonies Rhodococcus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18791?source=related_link\">",
"      Clinical features; diagnosis; therapy; and prevention of Rhodococcus equi infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22378?source=related_link\">",
"      Microbiology and pathogenesis of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23991?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11833?source=related_link\">",
"      Whipple's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_59_37815="Patterns of esophageal pressurization in EPT";
var content_f36_59_37815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Patterns of esophageal pressurization in esophageal pressure topography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With compartmentalized pressurization (panel A) the swallowed bolus becomes trapped between the advancing peristaltic contraction and the outflow obstruction caused by a poorly relaxing EGJ in a patient with EGJ outflow obstruction. The black line indicated the 30 mmHg isobaric contour signifying that the compartmentalized pressurization exceeds 30 mmHg. Panel B illustrates panesophageal pressurization, spanning from the UES to the EGJ in a patient with type II achalasia. This patient also exhibits proximal esophageal pressurization associated with an isolated distal contraction later in that plot. Areas of bolus pressurization are characterized by areas of vertical lines on the 30 mmHg isobaric contour; they can be conceptualized as being the result of multiple pressure sensors being contained within an isobaric enclosed space.",
"    <div class=\"footnotes\">",
"     EGJ: esophagogastric junction; UES: upper esophageal sphincter.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37815=[""].join("\n");
var outline_f36_59_37815=null;
var title_f36_59_37816="Neonatal hyperglycemia";
var content_f36_59_37816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal hyperglycemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37816/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37816/contributors\">",
"     See Wai Chan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37816/contributors\">",
"     Ann R Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37816/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37816/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37816/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37816/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/59/37816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose supply and metabolism are of central importance for growth and normal brain development in the fetus and newborn. Disorders in glucose supply or metabolism can result in hypoglycemia or hyperglycemia. Hyperglycemia in the neonatal period is reviewed here. Neonatal hypoglycemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PARENTERAL GLUCOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infants who are preterm or ill require parenteral administration of glucose because adequate enteral feeding is delayed. Neonatal hyperglycemia often occurs in this setting.",
"   </p>",
"   <p>",
"    Immediately after birth, sufficient glucose is provided to avoid hypoglycemia, typically at a rate of 5 to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute. As an example, administration of 10 percent dextrose solution at 100",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day provides glucose at a rate of 7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute. Although dextrose is a hydrated form of glucose and is 91 percent glucose, the correction usually is not applied in clinical practice.",
"   </p>",
"   <p>",
"    The glucose infusion rate is increased to approximately 11 to 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute in the first two to three days after birth to provide calories for growth. In general, glucose infusion rates &gt;15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute are avoided, as this exceeds the ability of most infants to oxidize glucose and may promote excessive lipogenesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/50/27434?source=see_link&amp;anchor=H4#H4\">",
"     \"Parenteral nutrition in premature infants\", section on 'Glucose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of hyperglycemia is uncertain. It is often defined as blood glucose &gt;125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or plasma glucose &gt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    These glucose levels are frequently observed during glucose infusions in newborns, especially in extremely preterm infants, and may not require intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma osmolality increases by 1",
"    <span class=\"nowrap\">",
"     mosmol/L",
"    </span>",
"    for each 18",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    increase in plasma glucose concentration. Thus, a rise in glucose concentration from 110 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.1 to 11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    only increases osmolality by 5",
"    <span class=\"nowrap\">",
"     mosmol/L,",
"    </span>",
"    which is a relatively small change. More marked hyperglycemia is required to produce the osmotic diuresis and hyperosmolality that may be clinically important. Most neonatologists become concerned about hyperglycemia when the blood glucose concentration exceeds approximately 180 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10 to 11.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glucosuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose excretion in the urine in hyperglycemic neonates is determined by the degree of hyperglycemia and renal tubular reabsorptive capacity for glucose. Newborns have variable reabsorptive capacity for glucose, which may be particularly reduced in those who are ill or premature.",
"   </p>",
"   <p>",
"    The net effect is that glucosuria alone is not a good marker for hyperglycemia since it can occur at normal blood glucose concentrations. In one study of sick preterm infants 25 to 33 weeks gestation, for example, fractional glucose excretion varied widely and glucosuria was often seen at normal blood glucose concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/2\">",
"     2",
"    </a>",
"    ]. These variations presumably are related to immaturity of the proximal tubule.",
"   </p>",
"   <p>",
"    On the other hand, mild hyperglycemia may be associated with little or no glucosuria in infants with mature proximal tubules. This was illustrated in a study of newborns who were given glucose infusions; at a mean blood glucose concentration of 197",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    there was little glucosuria and no significant osmotic diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia typically occurs when a newborn cannot adapt to parenteral glucose infusion by decreasing endogenous glucose production or increasing peripheral glucose uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/4\">",
"     4",
"    </a>",
"    ]. This is usually related to an associated clinical condition.",
"   </p>",
"   <p>",
"    Hyperglycemia is more common in preterm than in term infants, although the mechanism is uncertain. Glucose production rate and regulation are comparable in moderately preterm and term infants. In both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic glucose production is suppressed by infusion of glucose (with or without amino acids), hyperglycemia, and insulin.",
"     </li>",
"     <li>",
"      Glucose production is not changed by intravenous lipid infusion.",
"     </li>",
"     <li>",
"      Circulating insulin concentrations increase appropriately with hyperglycemia and increase hepatic and peripheral glucose uptake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, insulin responses may be inappropriate in extremely low birth weight (ELBW) infants. In one study, 23 of 56 ELBW infants became hyperglycemic during intravenous glucose infusions that were incrementally increased to a maximum rate of 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute between days two and six of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/5\">",
"     5",
"    </a>",
"    ]. Baseline insulin levels were similar in hyperglycemic and euglycemic infants, but only 15 of 23 hyperglycemic infants had a normal insulin response.",
"   </p>",
"   <p>",
"    The inappropriate insulin response in hyperglycemic ELBW infants may be related to defective islet beta cell processing of proinsulin. In a study comparing 15 hyperglycemic to 12 normoglycemic ELBW infants during the first week of life, proinsulin levels were significantly higher in the hyperglycemic ELBW infants, who also needed higher insulin levels to reach euglycemia compared to normoglycemic infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suppression of hepatic glucose production in response to glucose infusion also varies in very immature infants and may be incomplete. In a series of 10 infants born at 25 to 30 weeks gestation, glucose production rates decreased from 4.3 to 1.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute as glucose infusion was increased from 1.7 to 6.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/7\">",
"     7",
"    </a>",
"    ]. Plasma concentrations of glucose and insulin also increased.",
"   </p>",
"   <p>",
"    What remains unclear is why the same degree of glucose infusion produces variable elevations in blood glucose in newborns. A possible contributing factor is increased secretion of counterregulatory hormones associated with stress (particularly epinephrine and cortisol). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=see_link&amp;anchor=H3#H3\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Response to hypoglycemia in normal subjects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of stress was demonstrated in a report of metabolic responses to glucose infusion in preterm infants (weight 700 to 1550 g) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/8\">",
"     8",
"    </a>",
"    ]. Measurements were made before and after infusion in controls and in infants who required assisted ventilation and were considered stressed. Stressed infants had higher levels of glucose and of cortisol compared with controls and were more likely to have hyperglycemia (13 of 18 versus 1 of 12 infants). This difference was not due to decreased insulin or increased cortisol levels, because, among the stressed infants, insulin levels were higher and cortisol levels lower in the hyperglycemic compared to euglycemic newborns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, neonatal hyperglycemia is associated with a clinical condition, rather than a specific disorder of glucose metabolism, and occurs in infants receiving intravenous glucose infusions. A rare cause of hyperglycemia is neonatal diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     High rates of glucose infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of 10 percent dextrose solution to meet maintenance fluid requirements in the first few days after birth typically results in glucose infusion rates of approximately 5 to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute. Rates that exceed 10 to 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute (in infants who do not have hyperinsulinemic hypoglycemia) may result in hyperglycemia, particularly in extremely low birth weight (ELBW) infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia during glucose infusion is common in premature infants, especially very low birth weight (VLBW) infants (birth weights below 1500 g). In a prospective study of continuous glucose monitoring of 188 VLBW infants during the first week of life, 80 percent of patients had glucose levels greater than 8",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (144",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    and a third had glucose levels greater than 10",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (180",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    for more than 10 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/9\">",
"     9",
"    </a>",
"    ]. Risk factors associated with hyperglycemia included increasing prematurity, small for gestational age, use of inotropic agents, lipid infusions, and sepsis. Other studies also demonstrate an increased risk of hyperglycemia with decreasing gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ELBW infants frequently develop hyperglycemia in the absence of high rates of glucose infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/13\">",
"     13",
"    </a>",
"    ]. Proposed underlying mechanisms include reduced insulin secretion, incomplete suppression of hepatic glucose production, and stress response resulting in counter hormone regulation.",
"   </p>",
"   <p>",
"    Several studies have found that hyperglycemia in extremely premature infants (gestational age less than 27 weeks) is associated with an increased risk of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/10,11,14\">",
"     10,11,14",
"    </a>",
"    ]. However, one study from a single NICU reported that hyperglycemia (defined as a glucose level &gt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [8.3",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    on two separate occasions) was not associated with death. Differences in study results may be due to lack of consensus in defining hyperglycemia and the number of episodes and duration of hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further research is needed to provide a better understanding of the consequences of hyperglycemia and determine which infants require therapy. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Definition'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Insulin therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In one report of 93 ELBW infants cared for at a single tertiary unit, persistent hyperglycemia during the first week of life, defined as plasma glucose &gt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    was associated with an increased risk of early death and severe (grade III and IV) intraventricular hemorrhage by 10 days of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stress response to critical illness (epinephrine and cortisol) may result in hyperglycemia, especially in preterm infants who require mechanical ventilation. The stress response also may be responsible for hyperglycemia occurring after surgery. In this setting, increased rates of fluid administration may also contribute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia may be a presenting sign of sepsis in an infant with previously normal blood glucose concentrations and no change in glucose infusion rate. Potential mechanisms include the stress response, decreased insulin release, and reduced peripheral utilization of glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of certain drugs can result in hyperglycemia. Hyperglycemia is a common complication of glucocorticoid therapy, especially in ELBW infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/17\">",
"     17",
"    </a>",
"    ]. It also has been noted following",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    administration; the mechanism may be suppression of insulin release or insulin insensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neonatal diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal diabetes is a rare cause of hyperglycemia, with an estimated incidence of one in 500,000 births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/19\">",
"     19",
"    </a>",
"    ]. It is defined as persistent hyperglycemia occurring in the first months of life that lasts more than two weeks and requires insulin for management. The majority of infants are small for gestational age, which may be related to decreased insulin secretion in the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/4\">",
"     4",
"    </a>",
"    ]. They present with weight loss, volume depletion, hyperglycemia, and glucosuria with or without ketonuria and ketoacidosis.",
"   </p>",
"   <p>",
"    Neonatal diabetes is caused by mutations in a number of genes that encode proteins that play a critical role in the normal function of the pancreatic beta-cell such as proteins that are subunits in the ATP-sensitive potassium channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/20\">",
"     20",
"    </a>",
"    ]. The course of neonatal diabetes is variable depending on the affected gene. Genetic mutations of the KIR6.2 subunit of the ATP-sensitive potassium channel can result in permanent neonatal diabetes mellitus, whereas mutations of the SUR1 subunit can result in either permanent or transient neonatal disease. In a series of 57 infants presenting before one month of age with hyperglycemia requiring insulin therapy for more than two weeks, the disorder was transient in 18, transient with recurrence between seven and 20 years of age in 13, and permanent in 26 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Transient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either paternal uniparental disomy of chromosome 6 or an unbalanced duplication of paternal chromosome 6 is present in the majority of cases of transient neonatal diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. Mutations of the imprinting gene",
"    <span class=\"nowrap\">",
"     ZAC/PLAG1,",
"    </span>",
"    a transcriptional regulator of the type 1 receptor for pituitary adenylate cyclase-activating polypeptide, (an important regulator of insulin secretion), at chromosome 6q24 has been shown to be the major cause of neonatal transient DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activating mutations of the ABCC8 gene that encodes SUR1, the type 1 subunit of the sulfonylurea receptor, can cause either transient or permanent neonatal diabetes as discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Permanent",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-half of patients with neonatal diabetes mellitus have a permanent form that is primarily due to gene mutations related to the ATP-sensitive potassium channel. In rare cases, permanent neonatal diabetes mellitus is due to pancreatic agenesis or hypoplasia. In one case series of four patients with developmental failure of the pancreas, who were products of a consanguineous kinship, a specific gene defect was not identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with permanent neonatal diabetes mellitus have mutations that affect the ATP-sensitive potassium channel (KATP channel), which regulates the release of insulin from pancreatic beta cells. Activating mutations increase the number of open KATP channels at the plasma membrane, hyperpolarizing the beta cells, and preventing the release of insulin.",
"   </p>",
"   <p>",
"    In contrast, inactivating mutations, described in children with persistent hyperinsulinemic hypoglycemia of infancy, reduce the number of open KATP channels, resulting in depolarization of the beta cells and persistent hypersecretion of insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The KATP channel is composed of a small subunit Kir6.2 that surrounds a central pore and four regulatory SUR1 subunits. Activating gene mutations that affect these subunits can prevent insulin release, resulting in hyperglycemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      KCNJ11 gene encoding Kir6.2 &ndash; The most common cause of permanent neonatal diabetes is due to activating mutations in the KCNJ11 gene, which encodes Kir6.2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. The diagnosis is made within the first two months of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/28\">",
"       28",
"      </a>",
"      ]. Infants are small for gestational age but exhibit postnatal catch-up growth with insulin therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/31\">",
"       31",
"      </a>",
"      ]. Affected patients can also have neurologic abnormalities including severe developmental delay, epilepsy, muscle weakness, and dysmorphic features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/28\">",
"       28",
"      </a>",
"      ]. These findings are also known as the DEND syndrome (developmental delay, epilepsy, neonatal diabetes) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Subcutaneous insulin was routinely used in the past to treat patients with this disorder. However, oral sulfonylurea therapy appears to be more effective in controlling hyperglycemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. In a study of 49 patients with neonatal diabetes due to activating mutations of KCNJ11 gene, 44 were able to discontinue insulin therapy after starting oral sulfonylurea therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/33\">",
"       33",
"      </a>",
"      ]. In patients switched to sulfonylurea therapy, insulin secretion and glycated hemoglobin (8.1 to 6.4 percent) improved.",
"     </li>",
"     <li>",
"      SUR1 &ndash; Activating mutations of the ABCC8 gene, which encodes SUR1 (the type 1 subunit of the sulfonylurea receptor), can cause both transient and permanent forms of neonatal diabetes. In a series of 73 patients with neonatal diabetes, nine had activating mutations of the ABCC8 gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/35\">",
"       35",
"      </a>",
"      ]. Two had permanent diabetes and the others had transient diabetes. The patients were diagnosed at a median of 32 days (range 3 to 125 days). Oral sulfonylurea therapy normalized glycemic control in patients with genetic mutations of SUR1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neonatal diabetes mellitus has also been associated with mutations in other genes including RfX6, IPF-1, EIF2AK3, GCK, FOXP3, PTF1A, GLIS3, and the Ins2 genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/36-53\">",
"     36-53",
"    </a>",
"    ]. In some cases, these mutations result in pancreatic agenesis or hypoplasia, or absent beta cells. As an example, patients with permanent neonatal diabetes mellitus due to Wolcott-Rallison syndrome (diabetes mellitus, exocrine pancreatic insufficiency, and multiple epiphyseal dysplasia) have been shown to have hypoplastic pancreatic islets and a mutation in the EIF2AK3 gene that encodes translation initiation factor 2-alpha kinase 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. FOXP3 mutations cause a rare, x-linked disorder that presents in infancy with autoimmune endocrinopathy, enteropathy, and eczema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25850?source=see_link\">",
"     \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions to reduce the blood glucose concentration are initiated at values above 180 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10 to 11.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The first step in management is to decrease the glucose infusion rate. Reducing the rate to 4 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute usually lowers the blood glucose concentration. In most cases, this is accomplished by reducing the concentration of the dextrose solution from 10 to 5 percent. If provided with parenteral nutrition solution and lipid emulsion, infants can maintain normoglycemia with the reduced glucose supply by gluconeogenesis from glycerol and amino acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, reducing the glucose infusion rate is a short-term solution because it results in decreased caloric intake and compromises growth. Glucose tolerance typically improves when enteral feedings are established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Insulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin improves glucose tolerance, allows provision of more calories, and promotes growth in infants who remain hyperglycemic at reduced glucose infusion rates. The exact indications for insulin therapy are not well defined. Most neonatologists would begin an insulin infusion in infants with persistent hyperglycemia (&gt;200 to 250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.1 to 13.9",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    despite reductions in glucose infusion rate, and in infants who fail to thrive because of reduced caloric intake.",
"   </p>",
"   <p>",
"    The efficacy of insulin therapy was illustrated by a study of 24 extremely low birth weight (ELBW) infants with glucose intolerance who were randomly assigned to receive standard intravenous therapy with glucose and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    with or without a continuous insulin infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/55\">",
"     55",
"    </a>",
"    ]. Over a mean duration of 15 days, insulin therapy resulted in significantly higher glucose infusion rates (20.1 versus 13.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min), greater nonprotein energy intake (124 versus 86",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day), and greater weight gain (20.1 versus 7.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) compared to control. There were no differences between groups in hypoglycemia, electrolyte abnormalities, chronic lung disease, or mortality.",
"   </p>",
"   <p>",
"    Benefit from insulin therapy was also demonstrated in a trial of 23 ELBW infants who became hyperglycemic while receiving glucose at a rate up to 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/5\">",
"     5",
"    </a>",
"    ]. The infants were randomly assigned to reduced glucose intake or to insulin infusion. The duration of caloric intake less than 60",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day was significantly shorter with the insulin infusion (4.1 versus 8.6 days). There were no differences in morbidity or mortality between the two groups.",
"   </p>",
"   <p>",
"    In infants receiving parenteral nutrition, improvement in glucose tolerance by continuous insulin infusion appears to be comparable with and without the addition of lipid emulsion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Routine early insulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine use of early insulin therapy in premature infants has been proposed to prevent catabolism, improve glucose control, and increase energy intake, which might improve growth. However, early insulin therapy does not appear to improve growth and may be associated with an increased risk of mortality at 28 days of age and hypoglycemia.",
"   </p>",
"   <p>",
"    This was illustrated in a multicenter, open-label trial of 389 very low birth weight (VLBW) infants (birth weights &lt;1500 g) who were randomly selected to receive either standard care for glycemic control or a parenteral infusion of 20 percent dextrose with early insulin therapy (0.05",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour) starting within 24 hours of birth until seven days of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/57\">",
"     57",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early insulin group had lower mean glucose levels compared to the standard care group (112 vs 121",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [6.2 vs 6.7",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      were less likely to be hyperglycemic (defined as serum glucose greater than 180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [10",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      for more than 10 percent of the first week of life (21 versus 33 percent), were able to receive greater amounts of glucose infusion (51 versus 43",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      per day), and had less weight loss during the first week of life.",
"     </li>",
"     <li>",
"      More patients who received early insulin had episodes of hypoglycemia (29 versus 17 percent), which was defined as serum glucose levels less than 47",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      for more than one hour.",
"     </li>",
"     <li>",
"      There were no differences between the groups in the primary end point of mortality at the expected date of delivery or in the secondary end points of sepsis, necrotizing enterocolitis, retinopathy of prematurity, and growth parameters (ie, weight, length, and head circumference) at 28 days of age. However, the early insulin group had a higher mortality rate at 28 days of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This trial was ended early because of concerns of futility with regard to outcomes and concern for potential harm from insulin therapy. Follow-up is ongoing to determine whether the increased incidence of hypoglycemia in the early insulin group had a detrimental effect on neurodevelopmental outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link&amp;anchor=H27#H27\">",
"     \"Neonatal hypoglycemia\", section on 'Neurodevelopmental outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these data, routine insulin therapy should NOT be used in VLBW infants. Insulin should, however, be used to treat hyperglycemia when reducing the glucose infusion rate to approximately 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute is ineffective or not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Amino acid infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin infusion during euglycemia reduces proteolysis and protein synthesis in preterm infants who are not also given amino acids. In a report of four ELBW infants at two to five days of age, whole body proteolysis and protein synthesis decreased by 20 percent during a continuous infusion of insulin (0.05",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour) and glucose (without amino acids) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/58\">",
"     58",
"    </a>",
"    ]. Glucose utilization doubled (8 to 16.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min) but there was no net anabolic effect. In addition, plasma lactate concentration tripled (2.1 to 5.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    possibly because the high rate of glucose infusion exceeded the maximal capacity for glucose oxidation. Whether administration of amino acids during insulin infusion would further reduce proteolysis or increase protein synthesis and improve protein balance is uncertain.",
"   </p>",
"   <p>",
"    Based upon the limited current data, we suggest amino acid solution and lipid emulsion also should be administered to infants receiving glucose infusion to provide substrate for gluconeogenesis, spare glucose utilization, and stimulate insulin release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Risk of hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood glucose concentration should be monitored frequently during insulin infusion, although the risk of hypoglycemia appears to be small. This was documented in a retrospective review of 34 ELBW infants who developed hyperglycemia and glucosuria while receiving parenteral nutrition and were treated with insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/59\">",
"     59",
"    </a>",
"    ]. Before therapy, mean blood glucose concentration was 195",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    while receiving glucose at a mean rate of 7.9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min. During insulin infusion, given for 1 to 58 days, blood glucose values of 25 to 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.4 to 2.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were detected in fewer than 0.5 percent of samples (26 episodes of hypoglycemia in 7368 samples) and no values &lt;25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    were seen.",
"   </p>",
"   <p>",
"    Similar findings were noted in another study of 10 ELBW infants treated with insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/60\">",
"     60",
"    </a>",
"    ]. Glucose measurements were normal (46 to 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.6 to 7.2",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    in 78 percent of samples and less than 24",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dose and target glucose levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/44/36551?source=see_link\">",
"     Regular insulin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    is usually diluted in normal saline to a concentration of 0.1",
"    <span class=\"nowrap\">",
"     units/mL.",
"    </span>",
"    In some centers, concentration of 0.5",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    is used.",
"   </p>",
"   <p>",
"    The initial step in management of a persistently elevated glucose level is administering a bolus insulin infusion via a syringe pump over 15 minutes at a dose between 0.05 and 0.1",
"    <span class=\"nowrap\">",
"     units/kg.",
"    </span>",
"    The blood glucose level is monitored every 30 to 60 minutes, and if it remains elevated, the insulin dose is repeated as a bolus every four to six hours. If the glucose level remains elevated after three bolus doses, a continuous infusion is considered at an initial rate of between 0.01 and 0.05",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour and is adjusted in small increments up to a maximum rate 0.1",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour to maintain glucose levels of 150 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3 to 11",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Tighter glycemic control aiming for glucose values substantially below 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    increases the risk of hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As glucose tolerance improves, the insulin infusion should be tapered and discontinued to avoid hypoglycemia. In general, reductions in the insulin infusion rate can be made more rapidly than can increases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Adherence of insulin to plastic tubing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plastic tubing used for infusion should be primed with insulin for at least 20 minutes before treatment because insulin nonspecifically binds to the tubing, resulting in decreased availability to the patient. In one report, recovery of insulin from effluent of primed polyvinyl chloride tubing at a flow rate of 0.2",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    was greater at one, two, four, and eight hours (42, 85, 91, and 95 versus 22, 38, 67, and 75 percent, respectively) compared to unprimed tubing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37816/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood glucose concentration should be monitored within 30 minutes to one hour of the start of the infusion and after any change in the rate of glucose or insulin infusion. Glucose concentration should be monitored hourly until stable, and then less frequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood glucose concentration should be monitored in all infants receiving intravenous glucose infusions. For most infants, daily monitoring is recommended until blood glucose concentration is stable. For ELBW, for stressed or septic infants, or for those receiving insulin infusion, more frequent monitoring is needed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants with blood glucose concentration greater than 180 to 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10 to 11.1",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      the glucose infusion rate should be decreased; this should be done by decreasing the concentration of infused glucose, as long as it does not go below 5 percent.",
"     </li>",
"     <li>",
"      Insulin therapy should be considered in neonates with persistent hyperglycemia (blood glucose &gt;200 to 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [11.1 to 13.9",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      despite reductions in glucose infusion rate, and in infants who fail to thrive because of reduced caloric intake. Therapy is initially administered as a bolus of insulin administered via a syringe pump over 15 minutes as a dose between 0.05 and 0.1",
"      <span class=\"nowrap\">",
"       units/kg.",
"       <br/>",
"       <br/>",
"       Continuous",
"      </span>",
"      insulin infusion should be considered in infants with persistent hyperglycemia (blood glucose &gt;200 to 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [11.1 to 13.9",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      despite reductions in glucose infusion rate and after administering three insulin boluses. Infusion begins at a rate between 0.01 to 0.05",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour and is adjusted in small increments up to a maximum rate of 0.1",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour to maintain blood glucose levels between 150 to 200",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Insulin therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteral feedings should be initiated as soon as possible in order to wean and discontinue parenteral nutrition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5121848\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased blood glucose levels (&gt;125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [6.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are often seen in neonates, especially in preterm infants who receive glucose infusions as parenteral nutrition. With marked hyperglycemia defined as glucose concentration exceeding 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    there is a marked increase in plasma osmolality resulting in osmotic diuresis and potential cellular injury due to significant fluid shifts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/50/27434?source=see_link&amp;anchor=H4#H4\">",
"     \"Parenteral nutrition in premature infants\", section on 'Glucose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the mechanisms are uncertain, it is speculated that the increased risk of hyperglycemia in preterm infants compared with term infants is due to poorer insulin response, incomplete suppression of hepatic glucose production, and increased secretions of counterregulatory hormones associated with stress. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, neonatal hyperglycemia is caused by the administration of parenteral glucose, especially in very low birth weight infants (birth weight below 1500 g). Other contributing conditions include stress response to critical illness, sepsis, and drugs associated with hyperglycemia, such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      and glucocorticoids. Rarely is neonatal hyperglycemia due to neonatal diabetes mellitus, which is caused by mutations in genes that encode for proteins that are involved with insulin release from the pancreatic beta-cell. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood glucose concentration should be monitored in all infants receiving intravenous glucose infusions. For most infants, daily monitoring is recommended until blood glucose concentration is stable. More frequent monitoring is recommended for extremely low birth weight infants (birth weight &lt;1000 g), stressed, or septic infants, or those receiving insulin infusion. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our practice, we use the following stepwise management approach for neonates whose blood glucose exceeds 180 to 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10 to 11.1",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In neonates receiving parenteral glucose infusion, the glucose infusion rate should be reduced by decreasing the concentration of infused glucose, as long as it does not go below 5 percent.",
"     </li>",
"     <li>",
"      Insulin therapy should be considered in neonates with persistent hyperglycemia (blood glucose &gt;200 to 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [11.1 to 13.9",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      despite reductions in glucose infusion rate and in infants who fail to thrive because of reduced caloric intake. Therapy is initially administered as a bolus of insulin administered via a syringe pump over 15 minutes as a dose between 0.05 and 0.1",
"      <span class=\"nowrap\">",
"       unit/kg.",
"      </span>",
"     </li>",
"     <li>",
"      Continuous insulin infusion should be considered in infants with persistent hyperglycemia (blood glucose &gt;200 to 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [11.1 to 13.9",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      despite reductions in glucose infusion rate and administration of three insulin boluses. Infusion begins at a rate between 0.01 and 0.05",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      per hour and is adjusted in small increments up to a maximum rate of 0.1",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour to maintain blood glucose level between 150 and 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (8.3 to 11.1",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Initiate enteral feeds as soon as possible.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/1\">",
"      Louik C, Mitchell AA, Epstein MF, Shapiro S. Risk factors for neonatal hyperglycemia associated with 10% dextrose infusion. Am J Dis Child 1985; 139:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/2\">",
"      Wilkins BH. Renal function in sick very low birthweight infants: 4. Glucose excretion. Arch Dis Child 1992; 67:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/3\">",
"      Cowett RM, Oh W, Schwartz R. Persistent glucose production during glucose infusion in the neonate. J Clin Invest 1983; 71:467.",
"     </a>",
"    </li>",
"    <li>",
"     Kalhan SC, Devaskar SU. Disorders of carbohydrate metabolism. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 9th ed, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. Vol 2, p.1497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/5\">",
"      Meetze W, Bowsher R, Compton J, Moorehead H. Hyperglycemia in extremely- low-birth-weight infants. Biol Neonate 1998; 74:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/6\">",
"      Mitanchez-Mokhtari D, Lahlou N, Kieffer F, et al. Both relative insulin resistance and defective islet beta-cell processing of proinsulin are responsible for transient hyperglycemia in extremely preterm infants. Pediatrics 2004; 113:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/7\">",
"      Sunehag A, Gustafsson J, Ewald U. Very immature infants (&lt; or = 30 Wk) respond to glucose infusion with incomplete suppression of glucose production. Pediatr Res 1994; 36:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/8\">",
"      Lilien LD, Rosenfield RL, Baccaro MM, Pildes RS. Hyperglycemia in stressed small premature neonates. J Pediatr 1979; 94:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/9\">",
"      Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. Prevalence and determinants of hyperglycemia in very low birth weight infants: cohort analyses of the NIRTURE study. J Pediatr 2010; 157:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/10\">",
"      Alexandrou G, Ski&ouml;ld B, Karl&eacute;n J, et al. Early hyperglycemia is a risk factor for death and white matter reduction in preterm infants. Pediatrics 2010; 125:e584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/11\">",
"      Kao LS, Morris BH, Lally KP, et al. Hyperglycemia and morbidity and mortality in extremely low birth weight infants. J Perinatol 2006; 26:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/12\">",
"      Blanco CL, Baillargeon JG, Morrison RL, Gong AK. Hyperglycemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities. J Perinatol 2006; 26:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/13\">",
"      Farrag HM, Cowett RM. Glucose homeostasis in the micropremie. Clin Perinatol 2000; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/14\">",
"      Hays SP, Smith EO, Sunehag AL. Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants. Pediatrics 2006; 118:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/15\">",
"      Soghier LM, Brion LP. Multivariate analysis of hyperglycemia in extremely low birth weight infants. J Perinatol 2006; 26:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/16\">",
"      White RH, Frayn KN, Little RA, et al. Hormonal and metabolic responses to glucose infusion in sepsis studied by the hyperglycemic glucose clamp technique. JPEN J Parenter Enteral Nutr 1987; 11:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/17\">",
"      Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (&lt;96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; :CD001146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/18\">",
"      al-Rubeaan K, Ryan EA. Phenytoin-induced insulin insensitivity. Diabet Med 1991; 8:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/19\">",
"      von M&uuml;hlendahl KE, Herkenhoff H. Long-term course of neonatal diabetes. N Engl J Med 1995; 333:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/20\">",
"      St&oslash;y J, Steiner DF, Park SY, et al. Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene. Rev Endocr Metab Disord 2010; 11:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/21\">",
"      Hermann R, Laine AP, Johansson C, et al. Transient but not permanent neonatal diabetes mellitus is associated with paternal uniparental isodisomy of chromosome 6. Pediatrics 2000; 105:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/22\">",
"      Shield JP. Neonatal diabetes: new insights into aetiology and implications. Horm Res 2000; 53 Suppl 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/23\">",
"      Kamiya M, Judson H, Okazaki Y, et al. The cell cycle control gene ZAC/PLAGL1 is imprinted--a strong candidate gene for transient neonatal diabetes. Hum Mol Genet 2000; 9:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/24\">",
"      Temple IK, Shield JP. Transient neonatal diabetes, a disorder of imprinting. J Med Genet 2002; 39:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/25\">",
"      Mackay DJ, Callaway JL, Marks SM, et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat Genet 2008; 40:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/26\">",
"      Chen R, Hussain K, Al-Ali M, et al. Neonatal and late-onset diabetes mellitus caused by failure of pancreatic development: report of 4 more cases and a review of the literature. Pediatrics 2008; 121:e1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/27\">",
"      Thomas P, Ye Y, Lightner E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet 1996; 5:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/28\">",
"      Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/29\">",
"      Gloyn AL, Cummings EA, Edghill EL, et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 2004; 89:3932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/30\">",
"      Vaxillaire M, Populaire C, Busiah K, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004; 53:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/31\">",
"      Slingerland AS, Hattersley AT. Activating mutations in the gene encoding Kir6.2 alter fetal and postnatal growth and also cause neonatal diabetes. J Clin Endocrinol Metab 2006; 91:2782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/32\">",
"      Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005; 54:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/33\">",
"      Pearson ER, Flechtner I, Nj&oslash;lstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/34\">",
"      Landau Z, Wainstein J, Hanukoglu A, et al. Sulfonylurea-responsive diabetes in childhood. J Pediatr 2007; 150:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/35\">",
"      Babenko AP, Polak M, Cav&eacute; H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/36\">",
"      Smith SB, Qu HQ, Taleb N, et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature 2010; 463:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/37\">",
"      Scharfmann R, Polak M. Transcribing neonatal diabetes mellitus. N Engl J Med 2010; 362:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/38\">",
"      Stoffers DA, Zinkin NT, Stanojevic V, et al. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997; 15:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/39\">",
"      Dodge JA, Laurence KM. Congenital absence of islets of Langerhans. Arch Dis Child 1977; 52:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/40\">",
"      Blum D, Dorchy H, Mouraux T, et al. Congenital absence of insulin cells in a neonate with diabetes mellitus and mutase-deficient methylmalonic acidaemia. Diabetologia 1993; 36:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/41\">",
"      Winter WE, Maclaren NK, Riley WJ, et al. Congenital pancreatic hypoplasia: a syndrome of exocrine and endocrine pancreatic insufficiency. J Pediatr 1986; 109:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/42\">",
"      Baumeister FA, Engelsberger I, Schulze A. Pancreatic agenesis as cause for neonatal diabetes mellitus. Klin Padiatr 2005; 217:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/43\">",
"      Del&eacute;pine M, Nicolino M, Barrett T, et al. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000; 25:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/44\">",
"      Thornton CM, Carson DJ, Stewart FJ. Autopsy findings in the Wolcott-Rallison syndrome. Pediatr Pathol Lab Med 1997; 17:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/45\">",
"      Stoffers DA, Stanojevic V, Habener JF. Insulin promoter factor-1 gene mutation linked to early-onset type 2 diabetes mellitus directs expression of a dominant negative isoprotein. J Clin Invest 1998; 102:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/46\">",
"      Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/47\">",
"      Sellick GS, Barker KT, Stolte-Dijkstra I, et al. Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet 2004; 36:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/48\">",
"      Sen&eacute;e V, Chelala C, Duchatelet S, et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet 2006; 38:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/49\">",
"      Sen&eacute;e V, Vattem KM, Del&eacute;pine M, et al. Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. Diabetes 2004; 53:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/50\">",
"      Nj&oslash;lstad PR, S&oslash;vik O, Cuesta-Mu&ntilde;oz A, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001; 344:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/51\">",
"      Colombo C, Porzio O, Liu M, et al. Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. J Clin Invest 2008; 118:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/52\">",
"      St&oslash;y J, Edghill EL, Flanagan SE, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A 2007; 104:15040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/53\">",
"      Edghill EL, Flanagan SE, Patch AM, et al. Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008; 57:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/54\">",
"      Sunehag AL, Haymond MW, Schanler RJ, et al. Gluconeogenesis in very low birth weight infants receiving total parenteral nutrition. Diabetes 1999; 48:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/55\">",
"      Collins JW Jr, Hoppe M, Brown K, et al. A controlled trial of insulin infusion and parenteral nutrition in extremely low birth weight infants with glucose intolerance. J Pediatr 1991; 118:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/56\">",
"      Kanarek KS, Santeiro ML, Malone JI. Continuous infusion of insulin in hyperglycemic low-birth weight infants receiving parenteral nutrition with and without lipid emulsion. JPEN J Parenter Enteral Nutr 1991; 15:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/57\">",
"      Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. Early insulin therapy in very-low-birth-weight infants. N Engl J Med 2008; 359:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/58\">",
"      Poindexter BB, Karn CA, Denne SC. Exogenous insulin reduces proteolysis and protein synthesis in extremely low birth weight infants. J Pediatr 1998; 132:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/59\">",
"      Binder ND, Raschko PK, Benda GI, Reynolds JW. Insulin infusion with parenteral nutrition in extremely low birth weight infants with hyperglycemia. J Pediatr 1989; 114:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/60\">",
"      Vaucher YE, Walson PD, Morrow G 3rd. Continuous insulin infusion in hyperglycemic, very low birth weight infants. J Pediatr Gastroenterol Nutr 1982; 1:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/61\">",
"      Alsweiler JM, Harding JE, Bloomfield FH. Tight glycemic control with insulin in hyperglycemic preterm babies: a randomized controlled trial. Pediatrics 2012; 129:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37816/abstract/62\">",
"      Fuloria M, Friedberg MA, DuRant RH, Aschner JL. Effect of flow rate and insulin priming on the recovery of insulin from microbore infusion tubing. Pediatrics 1998; 102:1401.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4981 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B64CF0B05F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37816=[""].join("\n");
var outline_f36_59_37816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5121848\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PARENTERAL GLUCOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glucosuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      High rates of glucose infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neonatal diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Transient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Permanent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Insulin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Routine early insulin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Amino acid infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Risk of hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dose and target glucose levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Adherence of insulin to plastic tubing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5121848\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/458?source=related_link\">",
"      Nutritional composition of human milk and preterm formula for the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/50/27434?source=related_link\">",
"      Parenteral nutrition in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_59_37817="Indications and diagnostic tests for Helicobacter pylori infection";
var content_f36_59_37817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications and diagnostic tests for Helicobacter pylori infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37817/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37817/contributors\">",
"     Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37817/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37817/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37817/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/59/37817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing for Helicobacter pylori can be divided into invasive and noninvasive techniques, based upon the need for endoscopy. The techniques may be direct (culture, microscopic demonstration of the organism) or indirect (using urease or an antibody response as a marker of disease). The choice of test depends upon issues such as cost, availability, clinical situation, population prevalence of infection, pretest probability of infection, and factors such as the use of proton pump inhibitors and antibiotics that may influence certain test results.",
"   </p>",
"   <p>",
"    This topic review will present the indications and appropriate means of testing for H. pylori, and will also discuss the individual tests. Treatment regimens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHEN TO TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of clinical circumstances in which testing for H. pylori is considered. Recommendations for diagnostic testing for H. pylori were first proposed by the National Institutes of Health (NIH) in 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/1\">",
"     1",
"    </a>",
"    ]. More recent guidelines were published in 2006 by the European Helicobacter Study Group (EHSG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/2\">",
"     2",
"    </a>",
"    ] and in 2007 by the American College of Gastroenterology (ACG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ACG recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACG guidelines include the following conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testing for H. pylori should be performed only if the clinician plans to offer treatment for positive results",
"     </li>",
"     <li>",
"      Testing is indicated in patients with gastric MALT lymphoma, active peptic ulcer disease, or a past history of documented peptic ulcer",
"     </li>",
"     <li>",
"      The test-and-treat strategy for H. pylori (ie, test and treat if positive) is a proven management strategy for patients with uninvestigated dyspepsia who are under the age of 55 years and have no \"alarm features\" (bleeding, anemia, early satiety, unexplained weight loss, progressive dysphagia, odynophagia, recurrent vomiting, family history of GI cancer, previous esophagogastric malignancy)",
"     </li>",
"     <li>",
"      Deciding which test to use in which situation relies heavily upon whether a patient requires evaluation with upper endoscopy and the strengths, weaknesses, and costs of the individual tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7949949\">",
"    <span class=\"h2\">",
"     Peptic ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori is a common cause of gastric and duodenal ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Uncomplicated duodenal ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori is present in the majority of patients with uncomplicated duodenal ulcers, especially if nonsteroidal antiinflammatory drugs are excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, it has been argued that no diagnostic method is cost-effective in such patients and that treatment should be empiric [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/4\">",
"     4",
"    </a>",
"    ]. However, H. pylori infection is absent in up to 27 percent of patients with endoscopically proven duodenal ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/3\">",
"     3",
"    </a>",
"    ]. Such patients appear to have a significantly worse outcome, especially when treated empirically for infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, confirmation of infection should be obtained. At the time of endoscopy, the diagnosis can be established with a biopsy urease test if the patient is not taking a proton pump inhibitor or other medication that could interfere with the test, or with a biopsy for histologic examination. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Biopsy urease testing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Histology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Uncomplicated gastric ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori infection is present in the majority of uncomplicated gastric ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/6\">",
"     6",
"    </a>",
"    ]. However, H. pylori negative gastric ulcers have been increasingly recognized. The surreptitious or unrecognized use of nonsteroidal antiinflammatory drugs may account for some of these cases.",
"   </p>",
"   <p>",
"    Testing for H. pylori infection should be performed before antibiotic treatment. One approach is to obtain biopsies from the ulcer's edge and base to exclude gastric cancer, as well as biopsies from at least two separate sites in the gastric mucosa distant from the ulcer to identify H. pylori organisms. Even if the biopsy does not indicate malignancy, confirmation of gastric ulcer healing is recommended in most instances within two to three months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Gastric ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Recently bleeding gastric or duodenal ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients found to have a bleeding duodenal or gastric ulcer should be tested for H. pylori. However, the accuracy of various methods to detect H. pylori may be affected in the presence of recent bleeding. The following conclusions were reached in a meta-analysis of studies evaluating diagnostic test characteristics in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity was low but specificity high for biopsy-based methods such as rapid urease test (67 and 93 percent, respectively), histology (70 and 90 percent), and culture (45 and 95 percent)",
"     </li>",
"     <li>",
"      With respect to noninvasive tests, sensitivity and specificity were 93 and 92 percent for the (13)C urea breath test, 87 and 70 percent for the stool antigen test, and 88 and 69 percent for serology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest a gastric mucosal biopsy at the time of the initial endoscopy unless it is impractical or difficult, such as with a blood-filled stomach. However, a negative result does not exclude H. pylori and another test (ideally a urea breath test) should be performed to confirm a negative result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24919?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis of peptic ulcer disease\", section on 'Helicobacter pylori testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a gastric mucosal biopsy is not obtained, testing can be performed preferentially with a urea breath test. Negative results should be confirmed with a different test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24919?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis of peptic ulcer disease\", section on 'Helicobacter pylori testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Past history of peptic ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a past history of peptic ulcer disease that has been documented by endoscopy or radiology but who have never been treated for H. pylori should be tested and, if positive, treated for H. pylori. Noninvasive testing by serology, stool, or breath is a reasonable approach in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Asymptomatic patients and family",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients without a history of peptic ulcer disease are usually",
"    <strong>",
"     not",
"    </strong>",
"    tested for H. pylori infection. A possible exception occurs in patients with a family history or fear of gastric carcinoma, particularly those of East Asian, Mesoamerican, or Eastern European descent in whom the incidence of gastric cancer may be increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Whether asymptomatic family members of patients treated for H. pylori infection should be tested (to reduce the risk of reinfecting the patient) is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Long-term PPI therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have confirmed increased corpus atrophy in H. pylori positive patients on long-term PPI therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. H. pylori eradication has been shown to induce regression of corpus glandular atrophy in H. pylori positive patients treated with long-term PPI therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/12\">",
"     12",
"    </a>",
"    ]. It is not known whether halting progression to atrophic gastritis reduces the risk of gastric cancer.",
"   </p>",
"   <p>",
"    The Maastricht III consensus report recommends that H. pylori testing be considered in patients who are receiving or are to receive long-term maintenance therapy with PPIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Functional dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to H. pylori testing in functional dyspepsia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several other settings in which H. pylori testing might be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to treatment with NSAIDs, particularly in patients expected to be taking NSAIDs continuously for weeks, months, or years (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      In patients with immune thrombocytopenia, as platelet counts may improve in patients treated for H. pylori [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In patients with otherwise unexplained iron deficiency anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In patients with otherwise unexplained vitamin B-12 deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of H. pylori can usually be established during endoscopy by one of three methods: biopsy urease test, histology, and, less commonly, bacterial culture. Choosing among these tests depends upon the clinical circumstance, the accuracy of the tests, and the relative costs. Endoscopy is",
"    <strong>",
"     not",
"    </strong>",
"    indicated solely for the purpose of establishing H. pylori status.",
"   </p>",
"   <p>",
"    General recommendations have been proposed by the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When endoscopy is indicated, the test of first choice is a urease test on an antral biopsy.",
"     </li>",
"     <li>",
"      Routine gastric histology is generally not necessary and is expensive.",
"     </li>",
"     <li>",
"      If a biopsy urease test is negative, H. pylori infection may be diagnosed by histology, culture (if available), breath testing, or fecal antigen testing. Serology can also be used but does not distinguish reliably between active and past infection. Furthermore, the positive predictive value of serology is poor in areas where the prevalence of H. pylori infection is low. Thus, stool or breath testing are better alternatives to serology.",
"     </li>",
"     <li>",
"      Biopsy urease tests have reduced sensitivity in patients taking PPIs and in patients with recent active gastrointestinal bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Biopsy urease testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antral biopsies can be tested for urease activity using several techniques that have similar diagnostic accuracy (commercially available kits include CLOtest, PyloriTek, and Hp-fast) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/16\">",
"     16",
"    </a>",
"    ]. One of the most widely used is the CLOtest (Campylobacter-Like Organism, Ballard Medical, Draper, UT). With this technique, one or two pieces of tissue are placed in an agar well that contains urea and a pH reagent. Urease cleaves urea to liberate ammonia, producing an alkaline pH and a resultant color change. The CLOtest may become positive as early as one hour after collection, but a final reading at 24 hours is recommended. One study found that increasing the number of specimens used for CLOtest from one to four increased the sensitivity of the test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Warming of the gel tests has also been recommended to speed the results. However, a survey of comparative trials of testing techniques and a specific prospective trial suggest that the time saved is small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the various commercially available kits are inexpensive, they require an expensive procedure to obtain tissue. The cost is greater than that of a simple diagnostic endoscopy due to the addition of the biopsy and the resultant \"upcoding\" of the procedure to EGD (esophagogastroduodenoscopy) with biopsy.",
"   </p>",
"   <p>",
"    Nevertheless, once endoscopy is being performed, biopsy urease testing is less expensive than histology. Thus, a potential cost-saving measure is to obtain additional samples for histopathology, but delay sending the specimens to the lab pending the results of biopsy urease testing. Alternatives if the likelihood of infection is high include serology, urea breath testing, or stool testing. These tests can also be used in such patients to help establish the diagnosis in patients who have a negative biopsy urease test.",
"   </p>",
"   <p>",
"    The sensitivity of biopsy urease tests is approximately 90 to 95 percent, and specificity is 95 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, false positive tests are unusual. However, false negative results can occur in patients with recent gastrointestinal bleeding or with the use of PPIs, H2 antagonists, antibiotics, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    -containing compounds. Obtaining tissue samples from the antrum and the fundus may increase the sensitivity of the test in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, a negative urease test in patients who are taking antisecretory therapy or any of the other medications discussed above does",
"    <strong>",
"     not",
"    </strong>",
"    rule out H. pylori infection. Since antisecretory therapy may also diminish numbers of bacteria detected by histology (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Histology'",
"    </a>",
"    below), serologic testing may be the best strategy for patients in whom the likelihood of infection remains high, but who have begun these medications prior to endoscopy and have a negative biopsy urease test. An alternative is to stop antisecretory therapy prior to endoscopy. The optimal duration of time needed after medications have been stopped has not been established, although four weeks is probably reasonable. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Urea breath testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rapid urease testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the desire to know a patient's H. pylori status before discharge from the endoscopy suite, specialized urea membrane kits have been designed specifically to give a result within one hour (PyloriTek, Serim Research, Elkhart, IN, and Helicocheck, Institute of Immunology, Co., Ltd., Tochigi, Japan). With these rapid urease testing (RUT) kits, biopsy specimens are sandwiched between a reagent strip with a pH indicator and a pad containing urea. One hour sensitivity and specificity are comparable (89 to 98 percent and 89 to 93 percent, respectively) to those seen with agar gel tests at 24 hours and superior to agar gel tests at one hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/16,20-22\">",
"     16,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The kits also include an internal set of positive and negative controls, making them exempt from the Clinical Laboratories Improvement Act (CLIA) regulations that are currently applied to agar gel testing. Beyond these logistic advantages, RUTs have not shown superiority to less expensive techniques. Their results are also affected by use of antisecretory medications and antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric biopsy can be helpful in making the primary diagnosis of H. pylori infection. It also provides additional information regarding the presence of gastritis (",
"    <a class=\"graphic graphic_picture graphicRef64354 graphicRef63916 \" href=\"mobipreview.htm?37/55/38778\">",
"     picture 1A-B",
"    </a>",
"    ) and the detection of intestinal metaplasia and mucosa-associated lymphoid tissue (MALT). The biopsy diagnosis and histology of acute and chronic H. pylori gastritis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30055?source=see_link\">",
"     \"Acute and chronic gastritis due to Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that several biopsies be taken from both the antrum and body of the stomach, especially when looking for evidence of multifocal atrophic gastritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intestinal metaplasia. The cost can be minimized if all samples are put into one container, although this approach is not recommended by most pathologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/23\">",
"     23",
"    </a>",
"    ]. Strategies for obtaining biopsies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30055?source=see_link\">",
"     \"Acute and chronic gastritis due to Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential problems with histologic examination include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The density of H. pylori can vary at different sites, possibly leading to sampling error [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interobserver variability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The sensitivity of histology may be decreased in patients taking antisecretory therapy, but is still higher in this setting than biopsy urease testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The accuracy of histologic diagnosis of H. pylori infection can be improved by using special stains such as Giemsa or specific immune stains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Brush cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brush cytology is rarely used in clinical practice, but it can be considered in patients with bleeding disorders that make forceps biopsy undesirable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/27\">",
"     27",
"    </a>",
"    ]. The sample obtained with brushing can be examined using standard Gram stain techniques or special staining if the results of the Gram stain are inconclusive. Brush cytology has a reported sensitivity of 95 to 98 percent and specificity of 96 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bacterial culture and sensitivity testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori has historically been difficult to culture, but techniques are improving. Although the sensitivity in vitro may not always predict response in vivo, concerns over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and macrolide resistance are growing and a standard definition of antibiotic resistance is being established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      resistance appears to vary with geography and is estimated to range from 80 to 90 percent in tropical countries and to be as high as 50 percent in some European countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The incidence of primary macrolide resistance is 4 to 12 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rates of resistance to various antibiotics were estimated in a study that included approximately 3400 H. pylori isolates from 17 antibiotic treatment trials conducted between 1993 and 1999 across the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    resistance was observed in 22 to 39 percent of the isolates (depending upon the method used to test for resistance), while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance was observed in 11 to 12 percent of isolates. Resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    was rare. Metronidazole resistance was significantly more common in women than in men (35 versus 23 percent). Antibiotic resistance increased gradually up to age 70 years, then declined significantly. Regional differences in antimicrobial resistance were not observed.",
"   </p>",
"   <p>",
"    Routine culture for H. pylori is not currently recommended. However, patients with refractory disease may benefit from culture and sensitivity testing, since the incidence of resistance is very high in this subgroup. Biopsies for culture should be obtained before the forceps are contaminated with formalin. The tissue should be placed into a container with a few drops of saline. This preparation will allow for culture and sensitivity testing on-site or for transport to a central facility.",
"   </p>",
"   <p>",
"    Real-time polymerase chain reaction (RT-PCR) and in situ hybridization techniques can also be used to detect Helicobacter in biological specimens including gastric biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/33\">",
"     33",
"    </a>",
"    ], but these approaches are rarely used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NONINVASIVE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of noninvasive tests for the diagnosis of H. pylori are available or being evaluated. These include urea breath testing (UBT), stool antigen testing, and serology. In the past, post-treatment testing was recommended only for patients with complicated ulcer disease or with persistent or recurrent symptoms. However, because the costs of noninvasive stool and breath tests have fallen and because antibiotic resistance is increasing, it is now reasonable to confirm eradication of infection in all patients four to six weeks following treatment, although guidelines vary as to when such confirmation is recommended. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Confirmation of eradication'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Urea breath testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urea breath testing is based upon the hydrolysis of urea by H. pylori to produce CO2 and ammonia. A labeled carbon isotope is given by mouth; H. pylori liberate tagged CO2 that can be detected in breath samples.",
"   </p>",
"   <p>",
"    Two UBTs have obtained FDA approval: the non-radioactive 13C test (Meretek, Otsuka Pharmaceuticals), and the radioactive 14C test (Tri-Med, Ballard Medical Devices). Both tests can be performed in 15 to 20 minutes and have similar cost and accuracy. Some physicians prefer the 13C test since it does not use a radioactive isotope. The dose of radiation in the 14C test is minimal (approximately 1 microCi) and equivalent to one day of background radiation exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/34\">",
"     34",
"    </a>",
"    ]. Even though this dose of radiation is small, it may still be better to use an alternative to 14C in young children and pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link&amp;anchor=H244750#H244750\">",
"     \"Radiation-related risks of imaging studies\", section on 'Special populations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity and specificity of UBT are approximately 88 to 95 percent and 95 to 100 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/35\">",
"     35",
"    </a>",
"    ]. False positive results are therefore uncommon. False negative results may be observed in patients who are taking antisecretory therapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    , or antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. To reduce false negative results, the patient should be off antibiotics for at least four weeks and off PPIs for at least two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/38\">",
"     38",
"    </a>",
"    ]. On the other hand, in patients hospitalized for upper gastrointestinal bleeding, early diagnosis of H. pylori may improve the likelihood that the patient is discharged with effective therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, UBT should be considered as soon as the patient has begun an oral diet.",
"   </p>",
"   <p>",
"    The effect of PPIs, which is presumably due to suppression of H. pylori, was illustrated in a series of 93 patients who had H. pylori infection documented by UBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/37\">",
"     37",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    (30 mg orally once daily for 28 days) was associated with a negative result on subsequent urea breath testing in 33 percent. Repeat testing at 3, 7, and 14 days after stopping lansoprazole revealed positive breath tests in 91, 97, and 100 percent, respectively. A second study of 60 patients with biopsy-proven H. pylori infection who underwent UBT testing 7 and 14 days after treatment with lansoprazole demonstrated false positive rates of up to 40 percent with lansoprazole and up to 55 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory-based serologic testing using ELISA technology to detect IgG antibodies is inexpensive, noninvasive, and well suited to primary care practice. However, concerns over its accuracy have limited its use. Large studies have found uniformly high sensitivity (90 to 100 percent), but variable specificity (76 to 96 percent); the accuracy has ranged from 83 to 98 percent. Serologic tests require validation at the local level, which is impractical in routine practice. Local prevalence of H. pylori affects the positive predictive value (PPV) of antibody testing. In areas where the prevalence of H. pylori is less than 20 percent, as in much of the United States, a positive result on serologic testing represents active infection approximately 50 percent of the time. As the low accuracy of serology would result in inappropriate treatment in significant numbers of patients, guidelines recommend that serologic testing should not be used in low prevalence populations; testing for active infection with stool antigen assay or UBT is recommended in these populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/2,3,41\">",
"     2,3,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The new Maastricht IV guidelines endorse a limited role of locally validated serology assays (those with sensitivity greater than 90 percent) in patients on PPI therapy who cannot stop therapy for two weeks prior to the preferred tests of active infection (stool antigen test, breath test, rapid urease test) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the impracticality of local validation and the low positive predictive value of serology are still of concern in this setting.",
"   </p>",
"   <p>",
"    Inaccurate serological tests are also more common in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/42\">",
"     42",
"    </a>",
"    ] and in patients with cirrhosis in whom specificity can be compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/43\">",
"     43",
"    </a>",
"    ]. As a result, other techniques are preferred in these settings.",
"   </p>",
"   <p>",
"    Approaches to patients with positive or negative serologic tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient with a confirmed ulcer and a high pretest probability of infection, it is reasonable to initiate treatment based upon positive serology and to consider confirming a negative serology result with a second non-serologic test.",
"     </li>",
"     <li>",
"      In a patient with a low pretest probability for infection, a negative test is helpful to exclude infection. An example would be a young individual with dyspepsia and no evidence of peptic ulcer disease especially in an area where the prevalence of H. pylori is low (such as most of the United States). A positive serologic test in this setting is more likely to be a false-positive. As a result, secondary testing with a stool or breath test to confirm the initial result is appropriate before initiating treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conversion of positive serology to negative after treatment suggests bacterial cure. In one study, for example, 23 healthy adults with H. pylori infection demonstrated by gastric biopsy underwent quantitative testing for serum anti-H. pylori IgG at baseline, one month, three months, and approximately 18 months after completion of antibiotic therapy aimed at eradicating H. pylori [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/44\">",
"     44",
"    </a>",
"    ]. Follow-up endoscopy with biopsy showed eradication of H. pylori in 15 patients. Correlation of serology results with H. pylori eradication revealed the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients cured of infection, H. pylori titers declined by approximately 50 percent at three months",
"     </li>",
"     <li>",
"      At 18 months, 9 of 15 subjects (60 percent) cured of infection had undetectable antibody titers",
"     </li>",
"     <li>",
"      Seroconversion from detectable to undetectable levels at 18 months after therapy had a sensitivity and specificity of 60 percent and 100 percent, respectively, for detecting the eradication of infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, obtaining serology following antibiotic treatment for H. pylori may be most useful in patients in whom confirmation of H. pylori eradication is desired one year or more following therapy. However, this is rarely done in clinical practice except in settings where a patient cannot discontinue antisecretory therapies, a situation in which urea breath testing or stool antigen testing is less sensitive.",
"   </p>",
"   <p>",
"    The quantitative ELISA is generally used in research settings. It allows for determination of IgG titers of paired sera from the acute and convalescent (three to six months or longer) phase and can confirm eradication of the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Stool antigen assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of H. pylori in the stool of infected patients has led to the development of fecal assays, which are widely available and require no special set-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. A commercially available enzyme immunoassay is the recommended method for the primary diagnosis of H. pylori [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/3\">",
"     3",
"    </a>",
"    ]. The accuracy of the test was evaluated in a study involving 270 patients in whom the diagnosis of H. pylori was established by endoscopy and UBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/47\">",
"     47",
"    </a>",
"    ]. The sensitivity and specificity of the test were 94 and 86 percent, respectively. Similar results were found in a comparably designed study involving 272 infected patients (sensitivity 94 percent, specificity 92 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stool antigen assay is also useful for documenting whether eradication has been successful, although the data are heterogeneous and the earliest interval in which testing can be performed is unclear. In the study described above, the sensitivity and specificity for determining eradication after four weeks was 90 and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/48\">",
"     48",
"    </a>",
"    ]. Other reports have reached similar conclusions in patients in whom testing was performed four weeks after completing treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The test was predictive of eradication as early as seven days after completion of therapy (positive and negative predictive values of 100 and 91 percent, respectively) in a series of 84 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other studies have noted a lower predictive accuracy of the initially marketed polyclonal tests in the setting of post-eradication testing and in the setting of acute upper GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. In one, the test was falsely positive in 13 of 41 patients (32 percent) in whom H. pylori eradication was documented by endoscopy at five weeks after the start of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/51\">",
"     51",
"    </a>",
"    ]. False positive results have also been described in patients with acute upper gastrointestinal bleeding, possibly because of cross-reactivity with blood constituents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/52\">",
"     52",
"    </a>",
"    ]. Another report estimated that the stool antigen test could be associated with up to a 20 percent false negative rate when performed four to six weeks after eradication therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/53\">",
"     53",
"    </a>",
"    ]. Subsequently developed stool antigen assays using monoclonal antibodies were demonstrated to have higher sensitivity in the post-eradication testing than the initial tests using polyclonal antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/8\">",
"     8",
"    </a>",
"    ]. An overall estimate of sensitivity and specificity was 94 percent (95% CI 93 to 95 percent) and 97 percent (95% CI 96 to 98 percent), respectively. In eight studies evaluating both tests in the post-treatment setting, the sensitivity of the monoclonal technique was higher (91 versus 76 percent) than the polyclonal tests. Subsequent studies have demonstrated comparable accuracy between monoclonal stool antigen tests and UBT in the post-eradication setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The stool antigen test commercially available in the United States (Meridian Bioscience, Cincinnati, OH) has been converted to a monoclonal assay since 2006.",
"   </p>",
"   <p>",
"    The stool assay shares a limitation of tests that use urease as a marker for the organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/36,40\">",
"     36,40",
"    </a>",
"    ]. A study of 60 patients with biopsy-proven infection who were receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    showed false negative stool assays in up to 25 percent with lansoprazole and up to 15 percent with bismuth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/40\">",
"     40",
"    </a>",
"    ]. In contrast, false negative results were not observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    . These rates are lower than for UBT performed in a similar setting (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Urea breath testing'",
"    </a>",
"    above). However, for optimum results, the stool assay appears to require similar precautions for the initial diagnosis of H. pylori infection and for detecting eradication following therapy. In clinical situations where patients are unable or unwilling to stop PPI therapy two weeks prior to stool antigen testing, positive tests results are true positives; negative results may represent false negatives and should be confirmed with repeat testing two weeks after stopping PPI therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Rapid stool antigen tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stool antigen described above is performed in a laboratory, which delays diagnosis. A rapid H. pylori stool antigen test that can be performed during a clinic visit is available (Meridian Bioscience, Cincinnati, OH). Two large studies, one with 282 patients and the other with 240 patients, evaluated the rapid H. pylori stool test for the initial diagnosis and the confirmation of eradication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The sensitivities for initial diagnosis were 93 and 95 percent; the specificities for initial diagnosis were 89 and 87 percent. The sensitivities following eradication were 94 and 100 percent; the specificities following eradication were 97 and 91 percent.",
"   </p>",
"   <p>",
"    A decision analysis evaluating the cost-effectiveness of multiple testing strategies found stool antigen testing to offer greater accuracy at a modest increase in cost when compared with serology testing in populations with low to intermediate prevalence of H. pylori [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/58\">",
"     58",
"    </a>",
"    ]. A decision analysis evaluating cost-effectiveness in the setting of confirmation of eradication found stool testing to be the most cost-effective strategy, as compared with UBT and rapid urease testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Urea breath testing'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Rapid urease testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) is not practical for the routine diagnosis of H. pylori. It may, however, be useful in detecting the organism when ordinary culture is difficult, as with testing stool or drinking water. As discussed above, PCR can be performed on gastric tissues. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Bacterial culture and sensitivity testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Salivary assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral cavity can serve as a reservoir for H. pylori [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/60\">",
"     60",
"    </a>",
"    ]. Both saliva and dental plaque may contain H. pylori as demonstrated by serology and PCR. Although there is some appeal to being able to avoid venipuncture (particularly in children), studies indicate that IgG assays of saliva are not as sensitive as histology or serum testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Furthermore, because of the availability of breath tests and stool assays, assays of saliva are no longer used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Urinary assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A urine-based enzyme-linked immunosorbent assay was also developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/63,64\">",
"     63,64",
"    </a>",
"    ], with a reported sensitivity and specificity of 96 and 79 percent, respectively when compared with histology, and 98 and 96 percent, respectively when compared to serum antibody tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/63\">",
"     63",
"    </a>",
"    ]. Although other studies were subsequently reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/65\">",
"     65",
"    </a>",
"    ], ELISA of urine is no longer used for the diagnosis of H. pylori infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7949893\">",
"    <span class=\"h2\">",
"     13C-urea blood test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serodiagnostic test using a 13C-urea assay (Ez-HBT, Metabolic Solutions Inc, Nashua, NH) was approved by the US Food and Drug Administration as a noninvasive tool for diagnosis of H. pylori infection, but is rarely if ever used in clinical practice. This test is performed by measuring two serum specimens; one is taken before and the second 60 minutes after ingestion of a 13C-urea rich meal. The test has a reported sensitivity of 92 to 100 percent and a reported specificity of 96 to 97 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     CONFIRMATION OF ERADICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of eradication should be strongly considered for all patients receiving treatment for H. pylori because of the availability of accurate, relatively inexpensive, noninvasive tests (stool and breath tests) and increasing antibiotic resistance. Confirmation of eradication has been recommended by a European consensus panel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/2\">",
"     2",
"    </a>",
"    ]. A 2007 guideline from the American College of Gastroenterology recommends confirming eradication in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any patient with an H. pylori-associated ulcer",
"     </li>",
"     <li>",
"      Individuals with persistent dyspeptic symptoms despite the test-and-treat strategy",
"     </li>",
"     <li>",
"      Those with H. pylori-associated MALT lymphoma",
"     </li>",
"     <li>",
"      Individuals who have undergone resection of early gastric cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above recommendations are based largely on expert consensus agreement.",
"   </p>",
"   <p>",
"    Urea breath testing performed at least four weeks after treatment has been promoted as the test of choice to confirm eradication of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/2\">",
"     2",
"    </a>",
"    ]. Stool antigen testing is a more widely available alternative, but it may be less accurate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/53\">",
"     53",
"    </a>",
"    ]. Until further data are available, the stool antigen test should not be performed sooner than four to six weeks after completion of treatment because of both false-positive and false-negative results in this time period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/51,53\">",
"     51,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recent antibiotics taken for reasons other than H. pylori eradication or recent treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    or PPIs can affect test results. Antibiotics and bismuth should be discontinued for at least four weeks and PPIs at least one week, if possible, prior to testing to confirm eradication (with urea breath test, stool antigen testing, or endoscopic testing) to reduce the chance of false-negative results.",
"   </p>",
"   <p>",
"    Endoscopy with biopsy for culture can be performed when antibiotic resistance is suspected. A biopsy obtained for histopathology is appropriate if urea breath testing or stool antigen testing is not feasible or during follow-up of complicated ulcer disease. Serologic testing is not useful for follow-up since many patients continue to have antibodies for months or even years after eradication therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37817/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/46/1763?source=see_link\">",
"       \"Patient information: Gastritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who do not require endoscopic evaluation for evaluation of new onset dyspepsia (those under age 55 who do not have alarm symptoms), initial diagnosis of H. pylori should be made with a test for active infection (stool antigen or urea breath test). Serology, as it cannot differentiate between past or current infection and has a low positive predictive value in much of the United States, is not recommended in patients with a low pre-test probability. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Urea breath testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Stool antigen assay'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Endoscopic biopsy should be reserved for patients who are undergoing a diagnostic endoscopy and are found to have an ulcer and for those who require endoscopy to follow-up a gastric ulcer or for the diagnosis or follow-up of suspected MALT lymphoma. Biopsy urease testing can be performed in patients not taking antibiotics or a proton pump inhibitor (PPI) when histopathology is not required. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Endoscopic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest confirmation of eradication because of the availability of accurate, relatively inexpensive, noninvasive tests (stool and breath tests), and because of increased resistance to antibiotic therapy, at least four weeks after treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Confirmation of eradication'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/1\">",
"      NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/2\">",
"      Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/3\">",
"      Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/4\">",
"      Greenberg PD, Koch J, Cello JP. Clinical utility and cost effectiveness of Helicobacter pylori testing for patients with duodenal and gastric ulcers. Am J Gastroenterol 1996; 91:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/5\">",
"      Bytzer P, Teglbjaerg PS, Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001; 96:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/6\">",
"      Laine L. Helicobacter pylori, gastric ulcer, and agents noxious to the gastric mucosa. Gastroenterol Clin North Am 1993; 22:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/7\">",
"      Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/8\">",
"      Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/9\">",
"      Levi F, Lucchini F, Negri E, et al. Trends in cancer mortality in the European Union and accession countries, 1980-2000. Ann Oncol 2004; 15:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/10\">",
"      Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/11\">",
"      Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006; 23:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/12\">",
"      Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/13\">",
"      Rostami N, Keshtkar-Jahromi M, Rahnavardi M, et al. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. Am J Hematol 2008; 83:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/14\">",
"      DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 2005; 100:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/15\">",
"      Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/16\">",
"      Laine L, Lewin D, Naritoku W, et al. Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori. Gastrointest Endosc 1996; 44:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/17\">",
"      Siddique I, Al-Mekhaizeem K, Alateeqi N, et al. Diagnosis of Helicobacter pylori: improving the sensitivity of CLOtest by increasing the number of gastric antral biopsies. J Clin Gastroenterol 2008; 42:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/18\">",
"      Laine L, Estrada R, Lewin DN, Cohen H. The influence of warming on rapid urease test results: a prospective evaluation. Gastrointest Endosc 1996; 44:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/19\">",
"      Weston AP, Campbell DR, Hassanein RS, et al. Prospective, multivariate evaluation of CLOtest performance. Am J Gastroenterol 1997; 92:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/20\">",
"      Yousfi MM, el-Zimaity HM, Genta RM, Graham DY. Evaluation of a new reagent strip rapid urease test for detection of Helicobacter pylori infection. Gastrointest Endosc 1996; 44:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/21\">",
"      Young EL, Sharma TK, Cutler AF. Prospective evaluation of a new urea-membrane test for the detection of Helicobacter pylori in gastric antral tissue. Gastrointest Endosc 1996; 44:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/22\">",
"      Nishikawa K, Sugiyama T, Kato M, et al. A prospective evaluation of new rapid urease tests before and after eradication treatment of Helicobacter pylori, in comparison with histology, culture and 13C-urea breath test. Gastrointest Endosc 2000; 51:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/23\">",
"      Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/24\">",
"      Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc 1994; 40:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/25\">",
"      Faigel DO, Childs M, Furth EE, et al. New noninvasive tests for Helicobacter pylori gastritis. Comparison with tissue-based gold standard. Dig Dis Sci 1996; 41:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/26\">",
"      Wright CL, Kelly JK. The use of routine special stains for upper gastrointestinal biopsies. Am J Surg Pathol 2006; 30:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/27\">",
"      Narv&aacute;ez Rodr&iacute;guez I, Saez de Santamar&iacute;a J, Alcalde Rubio MM, et al. Cytologic brushing as a simple and rapid method in the diagnosis of Helicobacter pylori infection. Acta Cytol 1995; 39:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/28\">",
"      Huang MS, Wang WM, Wu DC, et al. Utility of brushing cytology in the diagnosis of Helicobacter pylori infection. Acta Cytol 1996; 40:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/29\">",
"      Mostaghni AA, Afarid M, Eghbali S, Kumar P. Evaluation of brushing cytology in the diagnosis of Helicobacter pylori gastritis. Acta Cytol 2008; 52:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/30\">",
"      M&eacute;graud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/31\">",
"      M&eacute;graud F. Rationale for the choice of antibiotics for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1995; 7 Suppl 1:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/32\">",
"      Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/33\">",
"      Liu H, Rahman A, Semino-Mora C, et al. Specific and sensitive detection of H. pylori in biological specimens by real-time RT-PCR and in situ hybridization. PLoS One 2008; 3:e2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/34\">",
"      Leide-Svegborn S, Stenstr&ouml;m K, Olofsson M, et al. Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test. Eur J Nucl Med 1999; 26:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/35\">",
"      Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/36\">",
"      Gatta L, Vakil N, Ricci C, et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/37\">",
"      Laine L, Estrada R, Trujillo M, et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998; 129:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/38\">",
"      Chey WD, Spybrook M, Carpenter S, et al. Prolonged effect of omeprazole on the 14C-urea breath test. Am J Gastroenterol 1996; 91:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/39\">",
"      Gisbert JP, Esteban C, Jimenez I, Moreno-Otero R. 13C-urea breath test during hospitalization for the diagnosis of Helicobacter pylori infection in peptic ulcer bleeding. Helicobacter 2007; 12:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/40\">",
"      Bravo LE, Realpe JL, Campo C, et al. Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Am J Gastroenterol 1999; 94:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/41\">",
"      Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/42\">",
"      Liston R, Pitt MA, Banerjee AK. IgG ELISA antibodies and detection of Helicobacter pylori in elderly patients. Lancet 1996; 347:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/43\">",
"      Nardone G, Coscione P, D'Armiento FP, et al. Cirrhosis negatively affects the efficiency of serologic diagnosis of Helicobacter pylori infection. Ital J Gastroenterol 1996; 28:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/44\">",
"      Feldman M, Cryer B, Lee E, Peterson WL. Role of seroconversion in confirming cure of Helicobacter pylori infection. JAMA 1998; 280:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/45\">",
"      Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterology 1994; 107:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/46\">",
"      Braden B, Teuber G, Dietrich CF, et al. Comparison of new faecal antigen test with (13)C-urea breath test for detecting Helicobacter pylori infection and monitoring eradication treatment: prospective clinical evaluation. BMJ 2000; 320:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/47\">",
"      Trevisani L, Sartori S, Galvani F, et al. Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces: a prospective pilot study. Am J Gastroenterol 1999; 94:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/48\">",
"      Vaira D, Malfertheiner P, M&eacute;graud F, et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet 1999; 354:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/49\">",
"      Manes G, Balzano A, Iaquinto G, et al. Accuracy of stool antigen test in posteradication assessment of Helicobacter pylori infection. Dig Dis Sci 2001; 46:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/50\">",
"      Vaira D, Vakil N, Menegatti M, et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002; 136:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/51\">",
"      Makristathis A, Pasching E, Sch&uuml;tze K, et al. Detection of Helicobacter pylori in stool specimens by PCR and antigen enzyme immunoassay. J Clin Microbiol 1998; 36:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/52\">",
"      van Leerdam ME, van der Ende A, ten Kate FJ, et al. Lack of accuracy of the noninvasive Helicobacter pylori stool antigen test in patients with gastroduodenal ulcer bleeding. Am J Gastroenterol 2003; 98:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/53\">",
"      Perri F, Manes G, Neri M, et al. Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments. Am J Gastroenterol 2002; 97:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/54\">",
"      Calvet X, S&aacute;nchez-Delgado J, Montserrat A, et al. Accuracy of diagnostic tests for Helicobacter pylori: a reappraisal. Clin Infect Dis 2009; 48:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/55\">",
"      Shimoyama T, Kobayashi I, Kato C, et al. Comparison of monoclonal antibody-based stool antigen tests to determine the results of Helicobacter pylori eradication therapy. Scand J Gastroenterol 2010; 45:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/56\">",
"      Wu DC, Wu IC, Wang SW, et al. Comparison of stool enzyme immunoassay and immunochromatographic method for detecting Helicobacter pylori antigens before and after eradication. Diagn Microbiol Infect Dis 2006; 56:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/57\">",
"      Veijola L, Myllyluoma E, Korpela R, Rautelin H. Stool antigen tests in the diagnosis of Helicobacter pylori infection before and after eradication therapy. World J Gastroenterol 2005; 11:7340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/58\">",
"      Vakil N, Rhew D, Soll A, Ofman JJ. The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori. Am J Gastroenterol 2000; 95:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/59\">",
"      Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004; 9:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/60\">",
"      Pytko-Polonczyk J, Konturek SJ, Karczewska E, et al. Oral cavity as permanent reservoir of Helicobacter pylori and potential source of reinfection. J Physiol Pharmacol 1996; 47:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/61\">",
"      Fallone CA, Elizov M, Cleland P, et al. Detection of Helicobacter pylori infection by saliva IgG testing. Am J Gastroenterol 1996; 91:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/62\">",
"      Luzza F, Maletta M, Imeneo M, et al. Salivary-specific immunoglobulin G in the diagnosis of Helicobacter pylori infection in dyspeptic patients. Am J Gastroenterol 1995; 90:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/63\">",
"      Kato M, Asaka M, Saito M, et al. Clinical usefulness of urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori: a collaborative study in nine medical institutions in Japan. Helicobacter 2000; 5:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/64\">",
"      Miwa H, Hirose M, Kikuchi S, et al. How useful is the detection kit for antibody to Helicobacter pylori in urine (URINELISA) in clinical practice? Am J Gastroenterol 1999; 94:3460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/65\">",
"      Leodolter A, Vaira D, Bazzoli F, et al. European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test. Aliment Pharmacol Ther 2003; 18:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/66\">",
"      Cutler AF, Toskes P. Comparison of [13C]urea blood test to [13C]urea breath test for the diagnosis of Helicobacter pylori. Am J Gastroenterol 1999; 94:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/67\">",
"      Ahmed F, Murthy UK, Chey WD, et al. Evaluation of the Ez-HBT Helicobacter blood test to establish Helicobacter pylori eradication. Aliment Pharmacol Ther 2005; 22:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37817/abstract/68\">",
"      Cutler AF, Prasad VM, Santogade P. Four-year trends in Helicobacter pylori IgG serology following successful eradication. Am J Med 1998; 105:18.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 18 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-11ACF9297B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37817=[""].join("\n");
var outline_f36_59_37817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHEN TO TEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACG recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7949949\">",
"      Peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Uncomplicated duodenal ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Uncomplicated gastric ulcer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Recently bleeding gastric or duodenal ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Past history of peptic ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Asymptomatic patients and family",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Long-term PPI therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ENDOSCOPIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Biopsy urease testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rapid urease testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Brush cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bacterial culture and sensitivity testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NONINVASIVE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Urea breath testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Stool antigen assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Rapid stool antigen tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Salivary assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Urinary assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7949893\">",
"      13C-urea blood test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      CONFIRMATION OF ERADICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/18\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/18|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/26/18858\" title=\"picture 1A\">",
"      H pylori gastritis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/15/30964\" title=\"picture 1B\">",
"      H pylori on crypt cells Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30055?source=related_link\">",
"      Acute and chronic gastritis due to Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24919?source=related_link\">",
"      Diagnosis of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/46/1763?source=related_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_59_37818="Anticoagulants other than heparin and warfarin";
var content_f36_59_37818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulants other than heparin and warfarin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37818/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37818/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37818/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37818/contributors\">",
"     Pier Mannuccio Mannucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/59/37818/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/59/37818/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/59/37818/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional anticoagulants in clinical use for the prevention or treatment of thromboembolic disease are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and its analogues and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . However, they have two major limitations: a narrow therapeutic window of adequate anticoagulation without bleeding, and a highly variable dose-response relation among individuals that requires monitoring by laboratory testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The variability of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is due in part to differences in bioavailability of subcutaneous heparin and to competitive occupation of binding sites (or in part to the significant nonspecific binding of heparin), by plasma proteins (other than antithrombin and coagulation factors), by proteins secreted by platelets (platelet factor 4), and by endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Furthermore, some of the heparin-binding proteins are acute phase reactants, the concentrations of which are increased in sick patients.",
"   </p>",
"   <p>",
"    Another limitation to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is a reduced ability to inactivate thrombin that is bound to fibrin and factor Xa that is bound to activated platelets within a thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/3\">",
"     3",
"    </a>",
"    ]. This may be due to the large size of the complex and to masking of the binding site(s) for heparin and AT on the thrombin molecule following the attachment of thrombin to fibrin or arterial wall matrix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/4\">",
"     4",
"    </a>",
"    ]. As a result, a thrombus may continue to grow during heparin therapy or clotting may be reactivated after heparin has been discontinued.",
"   </p>",
"   <p>",
"    These limitations have provided the impetus for the development of other antithrombotic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/5-13\">",
"     5-13",
"    </a>",
"    ]. The major examples of these newer anticoagulants are the factor Xa inhibitors and the direct thrombin inhibitors; some of these newer agents are orally active. The direct thrombin inhibitors, in contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , can inactivate fibrin-bound thrombin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factor Xa inhibitors and direct thrombin inhibitors and anticoagulants in development will be reviewed here. Efficacies of those agents that are available clinically are reviewed in detail separately in the discussions of the individual thromboembolic disorders.",
"   </p>",
"   <p>",
"    The uses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    as well as antiplatelet therapy with the glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonists are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link\">",
"     \"Therapeutic use of fondaparinux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF HEMOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before beginning this review, it is useful to summarize briefly the major steps in normal hemostasis and the importance of thrombin as an anticoagulant target.",
"   </p>",
"   <p>",
"    The three components of hemostasis (eg, platelet activation, clotting cascade, and fibrinolysis), while often discussed separately, are closely related to each other in vivo. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, the assembly of the two key clotting factor complexes, prothrombinase (factor Xa as the protease, factor Va as a cofactor, and prothrombin as the substrate) and tenase (factor IXa, factor VIII, and factor X), takes place on the activated platelet surface (",
"    <a class=\"graphic graphic_figure graphicRef75450 \" href=\"mobipreview.htm?12/20/12610\">",
"     figure 1",
"    </a>",
"    ). The cell surface-bound enzyme complexes markedly accelerate generation of the active enzymes, and protect the active enzymes from inhibition by their plasma protease inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. As a result, thrombin generation in vivo occurs in close proximity to activated platelets.",
"   </p>",
"   <p>",
"    Another illustration of the integration of the components of hemostasis is that arterial platelet-rich thrombi are relatively resistant to lysis. One potential reason is that platelets contain a large amount of plasminogen activator inhibitor-1 (PAI-1), the physiologic inhibitor of tissue-type plasminogen activator (tPA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. PAI-1 is released from activated platelets at the thrombus, contributing to its resistance to lysis by tPA or urokinase.",
"   </p>",
"   <p>",
"    Because of these interactions, the division of the antithrombotic agents into the three categories: anticoagulants, antiplatelet agents, and thrombolytic agents, is quite arbitrary. This should be kept in mind when we approach antithrombotic therapies from the anticoagulant, antiplatelet, and thrombolytic standpoints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clotting cascade",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simplified depiction of the clotting cascade is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef69920 \" href=\"mobipreview.htm?31/51/32574\">",
"     figure 2",
"    </a>",
"    ). Tissue factor (TF) is the physiologic initiator of clotting at a vascular wound. It is an absolute cofactor for factor VIIa (FVIIa), and the TF-FVIIa complex activates factor X, either directly or indirectly via activation of factor IX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/19\">",
"     19",
"    </a>",
"    ]. Factor Xa, in the presence of the cofactor factor Va and anionic phospholipid supplied by the activated cell surface, forms the prothrombinase complex, which activates prothrombin to thrombin.",
"   </p>",
"   <p>",
"    Factor XI plays a less important role in this scheme, functioning as a tertiary pathway of factor X activation. Thrombin feedback activates factor XI; factor XIa then activates factor IX, which leads to further thrombin formation after the clot has been formed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This lesser role is consistent with the clinical observation that bleeding complications are much less likely in patients with factor XI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/22\">",
"     22",
"    </a>",
"    ] deficiency compared with those with factor V or factor IX deficiency.",
"   </p>",
"   <p>",
"    One possible mechanism by which bleeding occurs in factor XI deficiency is increased fibrinolysis due to diminished activation of thrombin-activatable fibrinolysis inhibitor (TAFI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The relatively high concentration of thrombin required within the clot for activation of TAFI appears to come from thrombin-mediated factor XI activation after the clot has been formed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thrombin as an anticoagulant target",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombin is the final enzyme of the clotting cascade, and therefore the target of most of the current clinical anticoagulants. The structure of thrombin has been defined by X-ray crystallography. There is a deep groove on one side of the molecule, and the active site of the enzyme is buried deep within this groove. Access to the active site is protected by the surrounding amino acids, some of which protrude into the opening and shield the active site. Restricted access gives rise to some of the specificity of the enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Residues important in thrombin-activatable fibrinolysis inhibitor (TAFI) activation are located above the active site cleft, whereas residues involved in protein C activation are located below the active site cleft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the active site, there are two important positively charged patches at opposite poles on the thrombin molecule that represent sites for binding to macromolecular ligands: exosite I and exosite II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/25,26,28\">",
"     25,26,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exosite I is a major docking site, by which thrombin interacts with many of its physiologically relevant substrates, such as the thrombin receptor, fibrinogen, factor V, protein C, and thrombomodulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exosite II lies mostly on the back of the molecule and is spatially distinct from exosite I. Exosite II interacts with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and endogenous heparan sulfate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One class of thrombin inhibitors, the direct thrombin inhibitors, directly interacts with and inhibits the active site of thrombin and exosite I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/29\">",
"     29",
"    </a>",
"    ]. There are also indirect thrombin inhibitors:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    interacts with exosite II and antithrombin (AT) to inhibit thrombin; low molecular weight heparin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    interact with AT to inhibit factor Xa; and the heparinoid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    has an anticoagulant effect that is partially mediated by inhibition of thrombin via a combination of AT (heparin cofactor I) and heparin cofactor II. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Direct thrombin inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Heparin and antithrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombin (AT) neutralizes most of the enzymes in the clotting cascade, especially thrombin, factor Xa, and factor IXa, by forming equimolar, irreversible complexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/30\">",
"     30",
"    </a>",
"    ]. AT has two active functional sites, the reactive center, Arg393-Ser394, which binds to the active site of thrombin, and the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding site located at the amino terminus of the molecule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/30\">",
"     30",
"    </a>",
"    ]. The binding to heparin is mediated by a unique pentasaccharide sequence that is randomly distributed along the heparin chains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By itself, inhibition of thrombin and factor Xa by AT is relatively slow from the viewpoint of hemostasis, taking several minutes to reach completion. However, binding of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to the heparin binding site on AT produces a change in the three-dimensional tertiary structure of AT which accelerates the inactivating process by 1000- to 4000-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/30,31,33\">",
"     30,31,33",
"    </a>",
"    ]. AT makes contact with a few key residues around the active site of thrombin, but has no major direct interaction with exosite I, with or without heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced inactivation of thrombin requires the formation of a ternary complex in which heparin binds to both AT and to its binding site on thrombin, exosite II (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"mobipreview.htm?35/16/36110\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/36\">",
"     36",
"    </a>",
"    ]. This complex forms only on pentasaccharide-containing chains at least 18 saccharide units long; this is true of most chains of unfractionated heparin, is less common in low molecular weight heparins, and does not occur with the heparin pentasaccharide",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/31,37\">",
"     31,37",
"    </a>",
"    ]. There is no heparin-binding exosite on factor Xa; as a result, heparin interacts with factor Xa indirectly via AT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DANAPAROID",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     Danaparoid",
"    </a>",
"    is a low molecular weight heparinoid (ie, a heparan derivative), consisting of a mixture of heparan sulfate (83 percent), dermatan sulfate, and chondroitin sulfate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Its anticoagulant effect is mediated by inhibition of thrombin via a combination of AT (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor I) and heparin cofactor II, plus some undefined endothelial cellular mechanism. As a result of shortage in drug substance in the United States, the manufacturer (Organon) has decided to discontinue providing this medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIRECT THROMBIN INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant hirudin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    are examples of parenterally administered direct thrombin inhibitors;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    is an orally active direct thrombin inhibitor (",
"    <a class=\"graphic graphic_figure graphicRef69920 \" href=\"mobipreview.htm?31/51/32574\">",
"     figure 2",
"    </a>",
"    ). Part of the rationale for the clinical use of these drugs is their ability to inactivate clot-bound thrombin, which is not a property of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/3\">",
"     3",
"    </a>",
"    ]. Such clot-bound thrombin acts as an important thrombogenic stimulus, such as at a site of coronary thrombosis, particularly following clot disruption by thrombolytic agents. In comparison to heparin, the direct thrombin inhibitors, which are AT-independent, inhibit clot-bound thrombin because their sites for binding thrombin are not masked by fibrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/3,8,40,41\">",
"     3,8,40,41",
"    </a>",
"    ]. Direct thrombin inhibition can also overcome some of the other limitations of standard heparin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H5#H5\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Limitations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absence of binding to PF4 is important clinically since antibodies responsible for HIT are provoked by the complex of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and platelet factor 4 (PF4) on the platelet surface. Thus, it might be expected that a direct thrombin inhibitor can be used to treat HIT and, in fact, both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    have been approved for this purpose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As will be discussed below, the direct thrombin inhibitors have been studied in a number of different clinical settings, including treatment and prophylaxis of DVT, prevention of embolic stroke in patients with atrial fibrillation, and in the acute management of patients with unstable angina or myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirudin is a 65-amino-acid protein originally extracted from the salivary gland of the medicinal leech (Hirudo medicinalis). A few hirudin analogs are commercially available (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/60/25541?source=see_link\">",
"     desirudin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hirudin binds to thrombin via direct interaction with the active site, and the carboxyl tail of hirudin also binds to exosite I, giving rise to very high binding affinity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/44\">",
"     44",
"    </a>",
"    ]. The anticoagulant activity of hirudin is monitored by the aPTT. Its potential disadvantages are cost and the lack of an effective antidote. Subjects receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/60/25541?source=see_link\">",
"     desirudin",
"    </a>",
"    appear to develop antihirudin antibodies at a rate similar to that seen in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/45\">",
"     45",
"    </a>",
"    ]. Anaphylactoid reactions have been reported with hirudin and hirudin analogs. It has been suggested that patients previously treated with hirudin or its analogs, including desirudin itself, should not receive desirudin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    (hirulog) is a direct thrombin inhibitor frequently used for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention (PCI). It undergoes predominant non-organ elimination (proteolysis), and has a short half-life of approximately 25 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/47\">",
"     47",
"    </a>",
"    ]. Its affinity for thrombin is intermediate between that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    , explaining why it interferes with functional clotting assays to an extent intermediate between that achieved by these two other agents.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    in patients with unstable angina or myocardial infarction and in patients undergoing percutaneous coronary intervention is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H24#H24\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Direct thrombin inhibitors and fondaparinux'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22739310\">",
"    <span class=\"h2\">",
"     Argatroban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     Argatroban",
"    </a>",
"    is another direct thrombin inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/48\">",
"     48",
"    </a>",
"    ]. It is a small molecule that, in contrast to hirudin, interacts with the active site of thrombin but does not make contact with exosites I or II. It has a short in vivo plasma half-life, and is monitored by the aPTT, although dose-dependent changes are also seen in the prothrombin time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/49\">",
"     49",
"    </a>",
"    ]. Dosing precautions are recommended in patients with hepatic dysfunction; dose adjustment is apparently not required in the presence of renal impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multi-institutional phase III prospective trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    in HIT, as compared with historical controls, has been completed; as a result of these and other studies, the drug was approved in June 2000 by the FDA for prophylaxis or treatment of thrombosis in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    induced thrombocytopenia. Use of this agent in HIT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H37#H37\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Argatroban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     Argatroban",
"    </a>",
"    has also been evaluated as an adjunct to thrombolysis in patients with acute myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H21647326#H21647326\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Direct thrombin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13293573\">",
"    <span class=\"h3\">",
"     Lepirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     Lepirudin",
"    </a>",
"    is a recombinant hirudin approved for the treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, this drug is no longer available. The efficacy of lepirudin was demonstrated in a prospective series of 82 patients with confirmed HIT: 56 with thrombosis, 18 without thrombosis, and 8 undergoing cardiopulmonary bypass surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/52\">",
"     52",
"    </a>",
"    ]. The administration of lepirudin (0.1 to 0.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    bolus followed by 0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour infusion) was associated with a rapid increase in platelet count in 89 percent of patients, indicating the absence of crossreactivity with heparin-induced antibodies. The incidence of the combined endpoints (death, amputation, and new thromboembolic events) was significantly lower than in historical controls (25 versus 52 percent at day 35). The rate of bleeding was similar in the two groups. (See",
"    <a class=\"local\" href=\"#H13293580\">",
"     'Marketing of lepirudin discontinued'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H21256910#H21256910\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Lepirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adequate anticoagulant levels were documented by prolongation of the activated partial thromboplastin time (aPTT) 1.5 to 3.0-fold above baseline. Caution should be used in patients with renal insufficiency since the drug is cleared by the kidney and its anticoagulant effect is not easily reversed.",
"   </p>",
"   <p>",
"    Approximately 40 to 70 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    for more than five days develop antihirudin antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. These are not neutralizing antibodies and may actually enhance drug potency, perhaps by delaying its clearance from the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/56\">",
"     56",
"    </a>",
"    ]. As a result, the aPTT needs to be monitored on a regular basis in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13293580\">",
"    <span class=\"h4\">",
"     Marketing of lepirudin discontinued",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manufacturer of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    (Bayer HealthCare) has discontinued marketing of this product as of May 31, 2012. No further product is expected to be shipped to wholesalers in the United States, Canada, and the European Union after that date",
"    <a class=\"external\" href=\"file://www.fda.gov/drugs/drugsafety/drugshortages/ucm050794.htm\">",
"     FDA: drugs to be discontinued",
"    </a>",
"    . These actions are not related to safety concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Orally active agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of small molecule direct thrombin inhibitors under development, some of which are orally active.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dabigatran",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran etexilate",
"    </a>",
"    (Pradaxa) is an orally active direct thrombin inhibitor that has been employed for prevention and treatment of venous and arterial thromboembolic disorders in various clinical settings (eg, prevention of venous thromboembolism [VTE] after total knee or total hip arthroplasty, treatment of acute VTE, prevention of stroke in atrial fibrillation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/57-63\">",
"     57-63",
"    </a>",
"    ]. These clinical indications are discussed separately.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran etexilate",
"    </a>",
"    , the prodrug, is converted in the liver to the active compound",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , which then binds directly to thrombin with high affinity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10489655\">",
"    <span class=\"h4\">",
"     Pharmacokinetics and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    has a half-life of approximately 12 to 14 hours in adult volunteers with normal renal function, which requires twice daily dosing. Its absorption is unaffected by food. Maximum anticoagulant effects are achieved within two to three hours of ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/65\">",
"     65",
"    </a>",
"    ]. Renal excretion of unchanged drug is the predominant elimination pathway, with about 80 percent of an intravenous dose being excreted unchanged in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Drug clearance is longer in older adults and those with reduced renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/68\">",
"     68",
"    </a>",
"    ]. In one study, for example, dabigatran half-life was 13.8, 16.6, 18.7, 27.5, and 34 hours in normal volunteers, those with mild, moderate, and severe chronic kidney disease, and those receiving maintenance dialysis (ie, creatinine clearance &lt;10 to 20",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dose reductions have been suggested for some indications in the older adult (variously defined as &gt;75 or &gt;80 years of age) and in those with moderate or severe renal impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Canadian, UK and European Medicines Agency labeling,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      is contraindicated for use in patients with a creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (severe impairment) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/70-72\">",
"       70-72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the United States labeling,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      is not recommended for use in those with a creatinine clearance &lt;15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or in those who are hemodialysis dependent. Dose reduction has been recommended for those with a creatinine clearance in the range of 15 to 30",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      since such patients otherwise have had marked increases in bleeding events when taking full doses (ie, 150 mg twice daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The revised drug labeling indicates that renal function be assessed before starting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      and at least annually in those &gt;75 years of age or in those with a creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      It is unclear how to use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      in individuals with low body weight or those who are morbidly obese.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9884889\">",
"    <span class=\"h5\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    does not interact with the cytochrome P450 system. However, it is a substrate for the efflux transporter P-glycoprotein, and drug interactions may alter its efficacy. Its use in those taking certain P-glycoprotein inducers or inhibitors and those agents that alter dabigatran bioavailability (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ), has been considered contraindicated in some labeling (eg, systemic ketoconazole in the Canadian and UK labeling, and quinidine in the European Medicines Agency labeling) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/70-72,74\">",
"     70-72,74",
"    </a>",
"    ]. In other labeling, concurrent use of these agents should either be avoided, administration separated by at least two hours, or the dose of dabigatran should be appropriately modified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/70-72,75\">",
"     70-72,75",
"    </a>",
"    ]. Dabigatran drug interactions and management suggestions, along with contraindicated combinations according to the prescribing information in various countries, are described in the table (",
"    <a class=\"graphic graphic_table graphicRef61344 \" href=\"mobipreview.htm?24/0/24590\">",
"     table 1",
"    </a>",
"    ). In case of questions, the official prescribing information for dabigatran should be consulted along with the Lexi-Interact drug interactions program provided by UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9884896\">",
"    <span class=\"h5\">",
"     Drug stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the potential for product breakdown from moisture and loss of potency,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    capsules should only be dispensed and stored in the original bottle (with desiccant) or blister package. Patients should not store or place this agent in any other container, such as pill boxes or pill organizers. Once the bottle is opened, the pills inside must be used within four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/76\">",
"     76",
"    </a>",
"    ]. The capsules should not be crushed or opened before being administered. Accordingly, dabigatran should not be used in patients who require a feeding tube for ingestion of medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14130751\">",
"    <span class=\"h4\">",
"     Coagulation testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its predictable pharmacokinetics, routine monitoring of coagulation is not recommended for patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    . While the ecarin clotting time, which is not generally available, is the best method to assess bleeding risk in patients taking dabigatran, the dilute thrombin time and aPTT, and to a limited extent the activated clotting time, are the most accessible qualitative methods for determining the presence or absence of an anticoagulant effect of this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/65,68,77-82\">",
"     65,68,77-82",
"    </a>",
"    ]. A study that compared the PT, aPTT, and TT in plasma to which dabigatran had been added found that the TT was the most sensitive test for detecting low levels of dabigatran [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/83\">",
"     83",
"    </a>",
"    ]. This study found test-kit variability for all of these studies, emphasizing the need for caution when comparing tests from different studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    manufacturers. Some clinicians find the TT too sensitive, and prefer to use the aPTT to assess the presence of dabigatran.",
"   </p>",
"   <p>",
"    Despite the utility of these tests, none of these tests can universally identify patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    as being anticoagulated, since many of the available tests may yield normal results when trough levels of the drug are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/73\">",
"     73",
"    </a>",
"    ]. Specifically, point-of-care devices for measurement of the INR should",
"    <strong>",
"     not",
"    </strong>",
"    be used to monitor therapy with dabigatran [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10489662\">",
"    <span class=\"h4\">",
"     Efficacy in various conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific clinical indications for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention and treatment of venous thromboembolism &mdash; (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H24#H24\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Dabigatran etexilate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H24#H24\">",
"       \"Treatment of lower extremity deep vein thrombosis\", section on 'Dabigatran and rivaroxaban'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link&amp;anchor=H19#H19\">",
"       \"Anticoagulation in acute pulmonary embolism\", section on 'Dabigatran'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonvalvular atrial fibrillation &mdash; (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H4338483#H4338483\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Dabigatran'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14130785\">",
"    <span class=\"h4\">",
"     Reversal of dabigatran activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no antidote for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/85\">",
"     85",
"    </a>",
"    ]. Although clinical data are generally lacking, suggestions for reversing its anticoagulant effect have included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/65,66,68,73,82,86\">",
"     65,66,68,73,82,86",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H32\">",
"     'Emergency treatment of bleeding'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug discontinuation is usually sufficient to control bleeding in most clinical settings, since its half-life is relatively short (12 to 14 hours) in subjects with",
"      <strong>",
"       normal",
"      </strong>",
"      renal function.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       Dabigatran",
"      </a>",
"      is about one-third protein bound. It can be dialyzed in patients with renal impairment, with about 60 percent being removed after two to three hours of dialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/81,87\">",
"       81,87",
"      </a>",
"      ]. Charcoal hemofiltration has been suggested; and enhanced diuresis, if tolerated, is used to hasten renal excretion.",
"     </li>",
"     <li>",
"      Other drugs that may potentiate bleeding should be discontinued, if possible.",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      may remove unabsorbed drug from the gastrointestinal tract if given within two hours of ingestion.",
"     </li>",
"     <li>",
"      The use of unactivated 4 factor prothrombin complex concentrates (PCC), activated PCC (eg, FEIBA), or recombinant Factor VIIa in high doses has been suggested [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/86\">",
"       86",
"      </a>",
"      ]. These interventions involve a nontrivial risk of precipitating thromboembolism, and should be reserved for those with life-threatening bleeding;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study of 12 normal volunteers, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/20/25924?source=see_link\">",
"       4 factor unactivated prothrombin complex concentrates",
"      </a>",
"      (Cofact) did",
"      <strong>",
"       not",
"      </strong>",
"      reverse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      -associated prolongations in the aPTT, ecarin clotting time, or thrombin time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preliminary animal studies suggest that a dose of 50 to 100",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/61/37844?source=see_link\">",
"       activated prothrombin complex concentrates",
"      </a>",
"      (FEIBA) may be needed to reverse the in vivo, but not the in vitro, effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/65,88\">",
"       65,88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limited preclinical and clinical data suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"       recombinant human factor VIIa",
"      </a>",
"      may reverse the in vitro and in vivo anticoagulant effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/88,89\">",
"       88,89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/20/25924?source=see_link\">",
"       4 factor unactivated prothrombin complex concentrates",
"      </a>",
"      are available in Canada, Europe and other countries, but NOT in the United States, where only 3 factor PCCs (factor IX complex, Bebulin, Profilnine) are available. The 3 factor PCCs contain only minimal factor VII and therefore may not be as effective as 4 factor PCCs. The differences in these products are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Unactivated prothrombin-complex concentrates'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A monoclonal antibody capable of rapidly and completely inhibiting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    &rsquo;s anticoagulant activity in vitro and in vivo in a mouse bleeding model has been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/90\">",
"     90",
"    </a>",
"    ]. It is currently under further development for use in clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27804459\">",
"    <span class=\"h4\">",
"     Bleeding and thrombotic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have been raised about the safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    in terms of bleeding and thrombotic events due to post-market reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/91\">",
"     91",
"    </a>",
"    ]. The median age of those with bleeding events was 80 years, who may also have reduced renal function and other comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The United States FDA issued a statement in November 2012 that the rates of bleeding associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      did not appear to be higher than bleeding rates with the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      in patients who were using either drug for the first time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/94\">",
"       94",
"      </a>",
"      ]. This assessment was based on insurance claims and an administrative dataset.",
"     </li>",
"     <li>",
"      The European Medicines Agency concluded in May 2012 that the benefits of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      continue to outweigh the risks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/95\">",
"       95",
"      </a>",
"      ]. This group did propose updating product information for dabigatran to include assessment of renal function before initiating treatment and during treatment if deterioration in renal function is suspected, with avoidance of the drug in patients with severe renal impairment, as well as more detailed information regarding other situations in which the drug should not be used (eg, severe hepatic impairment, age &lt;18 years, lesion at risk of major bleeding, concomitant treatment with another anticoagulant, concomitant treatment with strong P glycoprotein inhibitors",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      , cyclosporin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of seven randomized trials of the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      indicated that use of this medication (when compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , or placebo controls) was associated with a significantly higher risk of myocardial infarction (MI) or acute coronary syndrome (ACS) (1.19 versus 0.79 percent, OR 1.33; 95% CI 1.03-1.71) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/97\">",
"       97",
"      </a>",
"      ]. The increased risk of MI and ACS was similar when using revised RE-LY trial results (OR 1.27) or after exclusion of short-term trials (OR 1.33).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations, as well as reports of deaths among trauma victims receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/80\">",
"     80",
"    </a>",
"    ], have called into question the safety of this agent, which has no antidote, as well as whether it should be used in trauma patients, older patients with renal disease and low body weight (eg, individuals at increased risk for excessive bleeding), or those with risk factors for MI or ACS (eg, those at increased risk of increased arterial thrombosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/13,97-99\">",
"     13,97-99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FACTOR Xa INHIBITORS",
"    </span>",
"   </p>",
"   <p>",
"    In addition to the direct and indirect thrombin inhibitors, there are a number of indirect factor Xa inhibitors that are being developed (",
"    <a class=\"graphic graphic_figure graphicRef69920 \" href=\"mobipreview.htm?31/51/32574\">",
"     figure 2",
"    </a>",
"    ), such as the tick or leech anticoagulant proteins and their derivatives, and synthetic analogs of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    pentasaccharide required for binding to antithrombin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/8,29,100-103\">",
"     8,29,100-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also a number of orally active direct factor Xa inhibitors under clinical development. In general, as a class of new anticoagulants, and similar to the direct thrombin inhibitors, they all have rapid onset of action, with peak anticoagulant effect achieved within two to four hours, thus potentially obviating the need for a parenteral anticoagulant (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight [LMW] heparin) in the initial treatment of VTE.",
"   </p>",
"   <p>",
"    These agents are also designed to have relatively stable pharmacodynamic profiles such that routine monitoring is not required, making them theoretically superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for long-term use. If indicated, anti-Xa activity can be measured using an aPTT assay similar to that employed for monitoring of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . However, the cost of these new factor Xa inhibitors will likely be substantially higher than that of warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Idraparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synthetic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    pentasaccharide",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    catalyzes factor Xa inactivation by AT without inhibiting thrombin (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"mobipreview.htm?35/16/36110\">",
"     figure 3",
"    </a>",
"    ). Idraparinux is a longer acting analogue of fondaparinux that can be given only once per week. Because of the concern about excessive bleeding following use of this agent, the development of idraparinux has been halted and focus has turned to a biotinylated version, Idrabiotaparinux (SSR 126517), which is discussed below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapeutic use of fondaparinux\", section on 'Longer-acting analogues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Idrabiotaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idrabiotaparinux (SSR 126517) is a biotinylated version of idraparinux. The rationale for this modification is that it provides a means to remove the drug from the circulation by intravenous infusion of avidin, which binds to the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    molecule attached to the drug. This neutralizes its anti-Xa activity, serving as an antidote and improving the benefit-to-risk profile of idraparinux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Phase III trials of this agent in DVT and PE are underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ultra low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVE5026 is a hemisynthetic, ultra low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , obtained by highly selective and controlled depolymerization of heparin, resulting in a structure strongly enriched in specific antithrombin-binding oligosaccharides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/109\">",
"     109",
"    </a>",
"    ]. It has an average molecular weight of 2000 to 3000 Da, as compared with other LMW heparins, which have a mean molecular weight of 4000 to 5000 Da. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Use of LMW heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AVE5026 appears to have nearly pure anti-factor Xa activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/109\">",
"     109",
"    </a>",
"    ]. It is currently in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Rivaroxaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    (BAY 59-7939, Xarelto) is an orally available direct factor Xa inhibitor with a bioavailability of 80 percent and peak plasma concentrations occurring 2.5 to 4 hours after oral administration. Dose-finding studies in patients undergoing orthopedic procedures suggested that an oral dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was suitable for investigation in phase III trials for the",
"    <strong>",
"     prevention",
"    </strong>",
"    of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/111-115\">",
"     111-115",
"    </a>",
"    ]. Similarly, a dose of 20 to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was deemed suitable for phase III trials investigating the",
"    <strong>",
"     treatment",
"    </strong>",
"    of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro studies have shown that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    did not cause platelet activation or aggregation in the presence of HIT antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/117\">",
"     117",
"    </a>",
"    ]. Furthermore, it did not cause the release of, or interact with, platelet factor 4, suggesting the potential use of this agent in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14130825\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific clinical indications for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention and treatment of venous thromboembolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H23#H23\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Rivaroxaban'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H24#H24\">",
"       \"Treatment of lower extremity deep vein thrombosis\", section on 'Dabigatran and rivaroxaban'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link&amp;anchor=H1712277#H1712277\">",
"       \"Anticoagulation in acute pulmonary embolism\", section on 'Rivaroxaban'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonvalvular atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H358919860#H358919860\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Rivaroxaban'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14130832\">",
"    <span class=\"h3\">",
"     Dosing and safety issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    has been approved in the United States, European Union (EU), and Canada for the prevention of venous thromboembolism in adults undergoing elective hip or knee replacement surgery, at a fixed oral dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    beginning after hemostasis has been established. This dose does not require laboratory monitoring or adjustment. Monitoring can be accomplished through the prothrombin time (PT), the activated partial thromboplastin time (aPTT), or measurement of anti-Xa activity, although in one study their alterations poorly reflected the circulating concentrations as determined by functional approaches (eg, thrombin generation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/77\">",
"     77",
"    </a>",
"    ]. The aPTT may be the more reliable test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/82,118,119\">",
"     82,118,119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The study protocol of the ROCKET-AF trial suggested discontinuation of the drug approximately two days before elective surgery without bridging anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/120\">",
"     120",
"    </a>",
"    ]. It can be resumed 6 to 10 hours after surgery, provided that hemostasis has been established, but it should not be given earlier than six hours after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/121\">",
"     121",
"    </a>",
"    ]. In cases of neuraxial anesthesia,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    should be resumed only after 24 hours following a traumatic puncture; an epidural catheter should not be removed sooner than approximately 24 hours after the last dose of rivaroxaban, and the next dose should not be administered until at least six hours after catheter removal.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    is not recommended for those with a creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and is considered contraindicated in those with a creatinine clearance &lt;15",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    as well as in those with significant hepatic impairment (Child-Pugh Class B and C with coagulopathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/69\">",
"     69",
"    </a>",
"    ]. Rivaroxaban has not been tested in individuals less than 18 years of age and is not recommended in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/121\">",
"     121",
"    </a>",
"    ]. Due to potential reproductive toxicity, rivaroxaban is contraindicated in pregnancy and not recommended during breastfeeding.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    interacts with drugs that are potent inhibitors of",
"    <strong>",
"     both",
"    </strong>",
"    CYP-3A4 and P-glycoprotein efflux transporter (eg, systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ), and concurrent use is contraindicated by Canadian product information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/70\">",
"     70",
"    </a>",
"    ]. Drugs that inhibit",
"    <strong>",
"     either",
"    </strong>",
"    CYP-3A4",
"    <strong>",
"     or",
"    </strong>",
"    P-glycoprotein, as opposed to both, do not seem to significantly alter rivaroxaban [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/122\">",
"     122",
"    </a>",
"    ]. Potent inducers of CYP-3A4 (eg, rifamycins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , St. John&rsquo;s wort) may reduce rivaroxaban&rsquo;s effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/74,122\">",
"     74,122",
"    </a>",
"    ]. Rivaroxaban drug interactions and management suggestions, as well as contraindicated drug combinations according to the prescribing information in various countries, are described in the table (",
"    <a class=\"graphic graphic_table graphicRef73141 \" href=\"mobipreview.htm?12/29/12766\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11071512\">",
"    <span class=\"h3\">",
"     Reversal of rivaroxaban activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the event of hemorrhage, standard measures should be employed, as there is no specific antidote for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/85\">",
"     85",
"    </a>",
"    ]. Suggestions for reversing its anticoagulant effect have included the following (see",
"    <a class=\"local\" href=\"#H32\">",
"     'Emergency treatment of bleeding'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug discontinuation is usually sufficient to control bleeding in most clinical settings, since its half-life is relatively short (five to nine hours) in subjects with normal renal function.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       Rivaroxaban",
"      </a>",
"      is over 90 percent protein bound. Accordingly, it cannot be dialyzed; charcoal hemofiltration has been suggested.",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      may remove unabsorbed drug from the gastrointestinal tract.",
"     </li>",
"     <li>",
"      Where there is life-threatening bleeding, the use of unactivated or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/61/37844?source=see_link\">",
"       activated prothrombin complex concentrates",
"      </a>",
"      (PCC) has been suggested, although experience is limited mainly to animal models and normal non-bleeding volunteers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a rabbit hemorrhagic model,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/20/25924?source=see_link\">",
"       4 factor unactivated prothrombin complex concentrates",
"      </a>",
"      (Kaskadil) did not reverse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      -induced bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a preliminary report,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/61/37844?source=see_link\">",
"       activated prothrombin complex concentrates",
"      </a>",
"      (FEIBA) at a dose of 50 to 100",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      was reported to correct the bleeding time in baboons treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/124\">",
"       124",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 12 normal, non-bleeding volunteers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/20/25924?source=see_link\">",
"       4 factor unactivated prothrombin complex concentrates",
"      </a>",
"      (Cofact) was able to reverse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      -associated prolongation in the PT and to normalize the endogenous thrombin potential [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study in 10 normal, non-bleeding volunteers, both activated (FEIBA) and unactivated 4 factor prothrombin complex concentrates (Kanokad) corrected",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      -induced impaired thrombin generation in a dose-dependent manner [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/125\">",
"       125",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/20/25924?source=see_link\">",
"       4 factor unactivated prothrombin complex concentrates",
"      </a>",
"      are available in Canada, Europe and other countries, but NOT in US where only 3 factor PCCs are available (factor IX complex, Bebulin, Profilnine). The 3 factor PCCs contain only minimal factor VII and therefore may not be as effective as 4 factor PCCs. The differences in these products are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Unactivated prothrombin-complex concentrates'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Apixaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     Apixaban",
"    </a>",
"    (BMS-562247-01, Eliquis) is an orally active factor Xa inhibitor that can be administered at a fixed dose without monitoring.",
"   </p>",
"   <p>",
"    The specific clinical indications for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention and treatment of venous thromboembolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H3436597#H3436597\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Apixaban'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H7480111#H7480111\">",
"       \"Treatment of lower extremity deep vein thrombosis\", section on 'Apixaban'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonvalvular atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H147982962#H147982962\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Apixaban'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5818288\">",
"    <span class=\"h3\">",
"     Pharmacokinetic and safety issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little in the way of information concerning the safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    . The following information is known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No antidote is available",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       Apixaban",
"      </a>",
"      is approximately 87 percent protein bound. It is not expected to be dialyzable",
"     </li>",
"     <li>",
"      Renal excretion of the unchanged drug is 25 percent",
"     </li>",
"     <li>",
"      Its half-life is 8 to 15 hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       Apixaban",
"      </a>",
"      has minimal impact on the PT, INR, or aPTT at therapeutic concentrations, but factor Xa inhibition seems appropriately sensitive to detect its presence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/128\">",
"       128",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     Apixaban",
"    </a>",
"    drug interactions and management suggestions, along with contraindicated combinations according to the prescribing information in various countries, are described in the table (",
"    <a class=\"graphic graphic_table graphicRef87789 \" href=\"mobipreview.htm?7/56/8078\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492700\">",
"    <span class=\"h2\">",
"     Edoxaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edoxaban is an orally active factor Xa inhibitor used at a single daily dose of 30 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/129-131\">",
"     129-131",
"    </a>",
"    ]. The half life of edoxaban is in the range of the other factor Xa inhibitors (ie, 6 to 10 hours), but unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    and the direct thrombin inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , edoxaban is administered once daily, and its absorption is unaffected by food. Edoxaban is renally excreted and is a substrate for P glycoprotein.",
"   </p>",
"   <p>",
"    The specific clinical indications for the use of edoxaban are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of venous thromboembolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H9637947#H9637947\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Edoxaban'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonvalvular atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H147982501#H147982501\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Studies of anticoagulant monotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ANTICOAGULANTS IN DEVELOPMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Tissue factor and factor VII as potential targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recombinant form of tissue factor pathway inhibitor (TFPI), the physiologic inhibitor of the",
"    <span class=\"nowrap\">",
"     TF/FVIIa",
"    </span>",
"    complex, is being tested, and there are also specific",
"    <span class=\"nowrap\">",
"     TF/FVIIa",
"    </span>",
"    and factor VIIa inhibitors (eg, nematode anticoagulant protein) undergoing development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/132-135\">",
"     132-135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Factor V and factor VIII as combined targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the above anticoagulants target the active enzymes in the clotting cascade. An alternative method is to simultaneously target the two cofactors in the cascade, factor Va and factor VIIIa. There is a potential advantage in this approach. Inhibition of the cofactors dampens the clotting cascade but does not completely block the generation of thrombin as might occur with a thrombin inhibitor if present in excess. This problem may account for the relatively narrow therapeutic window observed for hirudin.",
"   </p>",
"   <p>",
"    One way of targeting both factor Va and factor VIIIa is to use recombinant activated protein C, which has been approved for treatment of advanced sepsis. Activated protein C, in association with protein S on phospholipid surfaces, proteolytically inactivates factors Va and VIIIa, thereby inactivating prothrombinase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other possibilities include a protein C activator such as soluble recombinant thrombomodulin which, when bound to thrombin, converts protein C to activated protein C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10788085\">",
"    <span class=\"h2\">",
"     Factor VIII inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;TB-402 is a human IgG4 monoclonal antibody that is a partial inhibitor of factor VIII. As a result of its long half-life (approximately three weeks), this agent may provide a prolonged antithrombotic effect after a single dose. This was demonstrated in a randomized phase II trial in patients following total knee replacement, in which a single postoperative intravenous injection of TB-402 was found to be as effective and safe as 10 days of the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for at least 10 days) in preventing postoperative VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Selective inhibition of the procoagulant properties of thrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of the above noted activated protein C approaches is based upon the premise that thrombin's procoagulant and anticoagulant properties can be dissociated and exploited. All of the active site inhibitors of thrombin inhibit both types of activities, and an ideal thrombin inhibitor may be one that will selectively inhibit its procoagulant properties while retaining thrombin's ability to activate protein C, thereby exploiting this powerful natural anticoagulant pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two experimental approaches to selective procoagulant inhibition are the creation of thrombin mutants and of molecules which act like thrombomodulin. A thrombin mutant (E229K) has been identified in which glutamic acid in position 229 in wild-type thrombin is replaced by lysine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/138\">",
"     138",
"    </a>",
"    ]. This protein has less than 1 percent of the procoagulant properties of wild-type thrombin, while retaining approximately 50 percent of its protein C activation capability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/139\">",
"     139",
"    </a>",
"    ]. As a result, it functions as an anticoagulant. It does not consume fibrinogen, clotting factors, or platelets, and, even at the peak of its anticoagulation effect, it does not prolong the bleeding time in contrast to hirudin or the platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonists.",
"   </p>",
"   <p>",
"    A small molecule has been identified that suppresses fibrinogen clotting and enhances protein C activation by thrombin, thereby functioning in part like a soluble thrombomodulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/140\">",
"     140",
"    </a>",
"    ]. This change in substrate specificity appears to be mediated by an alteration in thrombin's substrate recognition site, a mechanism seemingly different from the allosteric changes induced by thrombomodulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Recombinant soluble thrombomodulin (ART-123)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recombinant form of the extracellular domain of thrombomodulin has a long plasma half-life of two to three days after a subcutaneous injection, such that it can be given once every five to six days with maintenance of anticoagulant activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/141\">",
"     141",
"    </a>",
"    ]. In a phase II trial, ART-123 was shown to be efficacious for VTE prophylaxis following total hip replacement surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Factor IXa inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;REG1 consists of RB006, an injectable RNA aptamer that specifically binds and inhibits factor IXa, and RB007, the complementary oligonucleotide that neutralizes its anti-IXa activity if and when needed. Whether selective factor IXa inhibition produces an appropriate anticoagulant effect when combined with platelet-directed therapy in patients with stable coronary artery disease is the subject of ongoing trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/143,144\">",
"     143,144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27084758\">",
"    <span class=\"h2\">",
"     Factor XI inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;An antisense oligonucleotide targeting factor XI has been developed in a mouse model, which produced dose-dependent antithrombotic activity in various venous and arterial thrombosis models, comparable in degree with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/145\">",
"     145",
"    </a>",
"    ]. Such treatment did not result in bleeding, and could be effectively and rapidly reversed with plasma-derived factor XI concentrate. There are no ongoing trials of this agent in human subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Factor XIIa inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selective factor XIIa inhibitor rHA-Infestin-4 (recombinant human albumin fused to the factor XIIa inhibitor Infestin-4) is highly active in human plasma and profoundly protects mice and rats from pathologic thrombus formation while not affecting hemostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/146\">",
"     146",
"    </a>",
"    ]. This agent is being considered for the prevention and treatment of acute ischemic cardiovascular and cerebrovascular events in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16099903\">",
"    <span class=\"h1\">",
"     WHEN TO USE THESE NEWER ORAL ANTICOAGULANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direct thrombin inhibitors (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ) and the factor Xa inhibitors (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ) differ significantly from the vitamin K antagonists in terms of their onset of action, half-life, drug-drug interactions, need for monitoring, ability to monitor should this be called into question, as well as availability of antidotes in the case of excessive bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/120\">",
"     120",
"    </a>",
"    ]. Accordingly, the decision to use one of these agents rather than one of the vitamin K antagonists needs to take these differences into account. As examples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/120\">",
"     120",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients already taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for atrial fibrillation with excellent INR control may have little to gain by switching to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/147\">",
"       147",
"      </a>",
"      ]. Anticoagulant choice in patients with atrial fibrillation is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H1803752#H1803752\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Summary of anticoagulant monotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       Dabigatran",
"      </a>",
"      should be used with caution in patients with atrial fibrillation and signs of coronary disease, since there is some evidence for an increased risk of myocardial infarction or acute coronary syndrome when dabigatran is used in such patients. (See",
"      <a class=\"local\" href=\"#H27804459\">",
"       'Bleeding and thrombotic events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      once daily dosing is more convenient than these agents, which require more frequent dosing. Patients who are poorly compliant with warfarin&rsquo;s once-per day dosing may be even less compliant with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      , which requires twice daily dosing.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       Rivaroxaban",
"      </a>",
"      , with a shorter half-life than dabigatran, may be equally problematic should scheduled doses be missed. In contrast, warfarin monitoring with frequent INR checks is less convenient than these newer agents, which typically do not require monitoring.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      is preferred over",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      in those with reduced renal function (eg, creatinine clearance &le;30",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H485506384#H485506384\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Indications for and choice of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with gastrointestinal diseases, especially those with a history of bleeding, may not be ideal candidates for treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      because of the lack of an antidote to these newer agents.",
"     </li>",
"     <li>",
"      For patients with unexplained poor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      control, with a significant portion of time in sub-therapeutic INR range, the newer oral anticoagulants should be considered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/148\">",
"       148",
"      </a>",
"      ]. However as mentioned above, it is critical to determine that the INR instability is not due to poor compliance.",
"     </li>",
"     <li>",
"      Patients with a poor level of INR control because of unavoidable drug-drug interactions (such as frequent need for antibiotics or a large number of concomitant and variable medications) may do better with the new oral anticoagulants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     EMERGENCY TREATMENT OF BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of any anticoagulant is associated with an increased risk of bleeding. Unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the actions of which can be reversed using protamine and vitamin K, respectively, most of these newer anticoagulants do not have reversing agents or antidotes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/85,149-151\">",
"     85,149-151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of bleeding episodes in patients taking these newer agents is problematical, as there is little in the way of evidence to guide the management of these patients. A number of general measures have been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/65,151\">",
"     65,151",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid and continuous assessment of the patient's condition, including establishment of an effective airway, stable hemodynamic status, and optimal body temperature, blood pH, and electrolyte balance, including calcium.",
"     </li>",
"     <li>",
"      Assessment of the patient's coagulation status (eg, activity of the coagulation cascade (eg, aPTT, thrombin time), hemoglobin level, platelet count)",
"     </li>",
"     <li>",
"      Address mechanical causes of bleeding that may require invasive approaches (eg, endoscopy, radiologic interventions, surgery)",
"     </li>",
"     <li>",
"      Withdraw all of the anticoagulant from the patient's bedside and withdraw any remaining material from intravenous lines.",
"     </li>",
"     <li>",
"      Consider the use of prohemostatic agents (eg, antifibrinolytic agents,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      , recombinant factor VIIa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/59/37818/abstract/152\">",
"       152",
"      </a>",
"      ]) and appropriate doses of an antidote, if available.",
"     </li>",
"     <li>",
"      Consider modalities that may specifically remove the anticoagulant (eg, hemodialysis, hemoperfusion, plasmapheresis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/11/14515?source=see_link\">",
"       \"Patient information: Latest medicines to prevent blood clots (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of anticoagulants other than the heparins and vitamin K antagonists are either currently available or in clinical trials. Some of these are orally active.",
"     </li>",
"     <li>",
"      The mechanisms of action of the anticoagulants discussed here include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Direct inhibition of thrombin (eg, hirudin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"       argatroban",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inhibition of Factor Xa (eg, idraparinux,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inhibition of other coagulation factors (eg, tissue factor, factor VIIa, factor V, factor VIII, factor IXa)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of bleeding episodes in patients taking these newer agents is problematic, as most do not have antidotes. General guidelines for the supportive care of bleeding patients taking these agents are provided in the text. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Emergency treatment of bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the lack of effective antidotes for the newer orally active agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      ), there is insufficient evidence at this time for their long-term safety as well as their appropriate use in patients with hepatic or renal impairment, or risk factors for myocardial infarction or acute coronary syndromes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dabigatran'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14130832\">",
"       'Dosing and safety issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16099903\">",
"       'When to use these newer oral anticoagulants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/1\">",
"      Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/2\">",
"      Eitzman DT, Chi L, Saggin L, et al. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation 1994; 89:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/3\">",
"      Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/4\">",
"      Becker DL, Fredenburgh JC, Stafford AR, Weitz JI. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem 1999; 274:6226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/5\">",
"      Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003; 163:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/6\">",
"      Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 2005; 105:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/7\">",
"      Weitz JI, Hirsh J, Samama MM, American College of Chest Physicians. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:234S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/8\">",
"      Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008; 29:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/9\">",
"      Pipeline review: Last of the primary care blockbusters? New antithrombotics line up to unseat warfarin, heparins, plavix. Pharmaceuticals Approvals Monthly. F-D-C Reports 2008; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/10\">",
"      Becker RC. Next-generation antithrombin therapies. J Invasive Cardiol 2009; 21:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/11\">",
"      Mannucci PM, Franchini M. Old and new anticoagulant drugs: a minireview. Ann Med 2011; 43:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/12\">",
"      Franchini M, Mannucci PM. New anticoagulants in internal medicine: an update. Eur J Intern Med 2010; 21:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/13\">",
"      Mannucci PM, Nobili A, Garattini S. New drugs for thromboprophylaxis in atrial fibrillation. Eur J Intern Med 2012; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/14\">",
"      Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem 1985; 260:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/15\">",
"      Mann KG, Nesheim ME, Church WR, et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/16\">",
"      Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/17\">",
"      Fay WP, Eitzman DT, Shapiro AD, et al. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/18\">",
"      Stringer HA, van Swieten P, Heijnen HF, et al. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/19\">",
"      Banner DW. The factor VIIa/tissue factor complex. Thromb Haemost 1997; 78:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/20\">",
"      Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266:7353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/21\">",
"      von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86:3035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/22\">",
"      Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/23\">",
"      Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/24\">",
"      Minnema MC, Friederich PW, Levi M, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/25\">",
"      Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990; 249:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/26\">",
"      Gr&uuml;tter MG, Priestle JP, Rahuel J, et al. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 1990; 9:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/27\">",
"      Hall SW, Nagashima M, Zhao L, et al. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem 1999; 274:25510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/28\">",
"      Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci U S A 1994; 91:5518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/29\">",
"      Hirsh J, Weitz JI. New antithrombotic agents. Lancet 1999; 353:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/30\">",
"      Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/31\">",
"      Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/32\">",
"      Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/33\">",
"      Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest 1984; 74:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/34\">",
"      Myles T, Church FC, Whinna HC, et al. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes. J Biol Chem 1998; 273:31203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/35\">",
"      Tsiang M, Jain AK, Gibbs CS. Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin. J Biol Chem 1997; 272:12024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/36\">",
"      Danielsson A, Raub E, Lindahl U, Bj&ouml;rk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261:15467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/37\">",
"      Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255:10081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/38\">",
"      Danhof M, de Boer A, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992; 22:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/39\">",
"      Nurmohamed MT, Fareed J, Hoppensteadt D, et al. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan. Semin Thromb Hemost 1991; 17 Suppl 2:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/40\">",
"      Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 1994; 72:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/41\">",
"      Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/42\">",
"      Di Nisio M, Middeldorp S, B&uuml;ller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/43\">",
"      Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/44\">",
"      Tsuda Y, Szewczuk Z, Wang J, et al. Interactions of hirudin-based inhibitor with thrombin: critical role of the IleH59 side chain of the inhibitor. Biochemistry 1995; 34:8708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/45\">",
"      Greinacher A, Eichler P, Albrecht D, et al. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003; 101:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/46\">",
"      Desirudin (Iprivask) for DVT prevention. Med Lett Drugs Ther 2010; 52:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/47\">",
"      Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/48\">",
"      Clarke RJ, Mayo G, FitzGerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991; 83:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/49\">",
"      Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001; 85:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/50\">",
"      Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/51\">",
"      Jang IK, Brown DF, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/52\">",
"      Greinacher A, V&ouml;lpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/53\">",
"      Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995; 50:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/54\">",
"      Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/55\">",
"      Huhle G, Hoffmann U, Song X, et al. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999; 106:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/56\">",
"      Fischer KG, Liebe V, Hudek R, et al. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb Haemost 2003; 89:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/57\">",
"      Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/58\">",
"      Eriksson BI, Dahl OE, B&uuml;ller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/59\">",
"      Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/60\">",
"      RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/61\">",
"      Eriksson BI, Friedman RJ. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost 2009; 15 Suppl 1:25S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/62\">",
"      Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/63\">",
"      Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/64\">",
"      Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/65\">",
"      van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/66\">",
"      Stangier J, Rathgen K, St&auml;hle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/67\">",
"      Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/68\">",
"      Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/69\">",
"      Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72:1739.",
"     </a>",
"    </li>",
"    <li>",
"     file://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&amp;code=84384 (Accessed on March 23, 2011).",
"    </li>",
"    <li>",
"     file://www.medicines.org.uk/EMC/medicine/20759/SPC/Pradaxa+75+mg+hard+capsules/ (Accessed on March 23, 2011).",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (Accessed on March 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/73\">",
"      Gulseth MP, Wittkowsky AK, Fanikos J, et al. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy 2011; 31:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/74\">",
"      Eikelboom JW, Weitz JI. New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. BMJ 2011; 342:c7270.",
"     </a>",
"    </li>",
"    <li>",
"     Pradaxa (dabigatran etexilate meslylate) US FDA licensed product information available at: file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=32032&amp;CFID=15739879&amp;CFTOKEN=2704dc395f28ebb2-626B0B78-AEB9-9D1F-6E6BFC1657FE6434&amp;jsessionid=ca30b497042b2e670797.",
"    </li>",
"    <li>",
"     Pradaxa (dabigatran etexilate) US prescribing information file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9 (Accessed on November 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/77\">",
"      Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/78\">",
"      Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/79\">",
"      Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/80\">",
"      Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med 2011; 365:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/81\">",
"      Warkentin TE, Margetts P, Connolly SJ, et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/82\">",
"      Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 2012; 69:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/83\">",
"      Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother 2012; 46:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/84\">",
"      van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012; 125:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/85\">",
"      Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011; 9:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/86\">",
"      Alberts MJ, Bernstein RA, Naccarelli GV, Garcia DA. Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke 2012; 43:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/87\">",
"      Wanek MR, Horn ET, Elapavaluru S, et al. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012; 46:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/88\">",
"      van Ryn J, Ruehl D, Priepki H, et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran by recombinant Factor VIIa or activated prothrombin complex concentrate (abstract 0370). Haematologica 2008; 98 (Suppl 1):148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/89\">",
"      Oh JJ, Akers WS, Lewis D, et al. Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 2006; 26:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/90\">",
"      Van Ryn J, Litzenburger T, Waterman A, et al. An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models (abstract P-MO-166 from the 2011 meeting of the ISTH). J Thromb Haemost 2011; 9:Suppl 2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/91\">",
"      Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/92\">",
"      Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/93\">",
"      Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171:1285.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm (Accessed on November 07, 2012).",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/05/WC500127771.pdf (Accessed on November 07, 2012).",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/05/WC500127777.pdf (Accessed on November 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/97\">",
"      Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/98\">",
"      Jacobs JM, Stessman J. Dabigatran: do we have sufficient data?: comment on \"Dabigatran association with higher risk of acute coronary events\". Arch Intern Med 2012; 172:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/99\">",
"      Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/100\">",
"      Herbert JM, H&eacute;rault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91:4197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/101\">",
"      Petitou M, H&eacute;rault JP, Bernat A, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999; 398:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/102\">",
"      Rosenberg RD. Redesigning heparin. N Engl J Med 2001; 344:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/103\">",
"      Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007; 115:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/104\">",
"      Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/105\">",
"      Spyropoulos AC. Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs 2007; 16:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/106\">",
"      Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010; 8:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/107\">",
"      Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011; 9:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/108\">",
"      B&uuml;ller HR, Gallus AS, Pillion G, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/109\">",
"      Viskov C, Just M, Laux V, et al. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost 2009; 7:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/110\">",
"      Lassen MR, Dahl OE, Mismetti P, et al. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study. J Thromb Haemost 2009; 7:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/111\">",
"      Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/112\">",
"      Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/113\">",
"      Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/114\">",
"      Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 2007; 97:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/115\">",
"      Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/116\">",
"      Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/117\">",
"      Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 2008; 143:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/118\">",
"      Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/119\">",
"      Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/120\">",
"      Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119:3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/121\">",
"      Turpie AG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/122\">",
"      Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/123\">",
"      Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/124\">",
"      Gruber A, Marzek UM, Buetehorn U, et al. Haematologica 2009; 92 (Suppl 2):181 (abstract 0449).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/125\">",
"      Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/126\">",
"      Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009; 86:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/127\">",
"      Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 2010; 29:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/128\">",
"      Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/129\">",
"      Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor xa inhibitor. Drugs 2011; 71:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/130\">",
"      Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126:2381.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.daiichisankyo.com/news/detail/004033.html (Accessed on November 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/132\">",
"      Stassens P, Bergum PW, Gansemans Y, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A 1996; 93:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/133\">",
"      Presta L, Sims P, Meng YG, et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001; 85:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/134\">",
"      Lee A, Agnelli G, B&uuml;ller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/135\">",
"      Giugliano RP, Wiviott SD, Stone PH, et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol 2007; 49:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/136\">",
"      Verhamme P, Tangelder M, Verhaeghe R, et al. Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial. J Thromb Haemost 2011; 9:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/137\">",
"      Hall SW, Gibbs CS, Leung LL. Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties. Cell Mol Life Sci 1997; 53:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/138\">",
"      Tsiang M, Paborsky LR, Li WX, et al. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry 1996; 35:16449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/139\">",
"      Leung LL, Hall SW. Dissociation of thrombin's substrate interactions using site-directed mutagenesis. Trends Cardiovasc Med 2000; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/140\">",
"      Berg DT, Wiley MR, Grinnell BW. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator. Science 1996; 273:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/141\">",
"      Moll S, Lindley C, Pescatore S, et al. Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2004; 2:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/142\">",
"      Kearon C, Comp P, Douketis J, et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005; 3:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/143\">",
"      Chan MY, Cohen MG, Dyke CK, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008; 117:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/144\">",
"      Cohen MG, Purdy DA, Rossi JS, et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010; 122:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/145\">",
"      Zhang H, L&ouml;wenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116:4684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/146\">",
"      Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/147\">",
"      Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/148\">",
"      Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/149\">",
"      Kessler CM. Current and future challenges of antithrombotic agents and anticoagulants: Strategies for reversal of hemorrhagic complications. Semin Hematol 2004; 41:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/150\">",
"      Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth 2002; 49:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/151\">",
"      Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111:4871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/59/37818/abstract/152\">",
"      Vavra KA, Lutz MF, Smythe MA. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. Ann Pharmacother 2010; 44:718.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1370 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37818=[""].join("\n");
var outline_f36_59_37818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF HEMOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clotting cascade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thrombin as an anticoagulant target",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Heparin and antithrombin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DANAPAROID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIRECT THROMBIN INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hirudin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22739310\">",
"      Argatroban",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13293573\">",
"      - Lepirudin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13293580\">",
"      Marketing of lepirudin discontinued",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Orally active agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dabigatran",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10489655\">",
"      Pharmacokinetics and dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H9884889\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H9884896\">",
"      - Drug stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14130751\">",
"      Coagulation testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10489662\">",
"      Efficacy in various conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14130785\">",
"      Reversal of dabigatran activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27804459\">",
"      Bleeding and thrombotic events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FACTOR Xa INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Idraparinux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Idrabiotaparinux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ultra low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Rivaroxaban",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14130825\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14130832\">",
"      - Dosing and safety issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11071512\">",
"      - Reversal of rivaroxaban activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Apixaban",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5818288\">",
"      - Pharmacokinetic and safety issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1492700\">",
"      Edoxaban",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ANTICOAGULANTS IN DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Tissue factor and factor VII as potential targets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Factor V and factor VIII as combined targets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10788085\">",
"      Factor VIII inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Selective inhibition of the procoagulant properties of thrombin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Recombinant soluble thrombomodulin (ART-123)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Factor IXa inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27084758\">",
"      Factor XI inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Factor XIIa inhibitor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16099903\">",
"      WHEN TO USE THESE NEWER ORAL ANTICOAGULANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      EMERGENCY TREATMENT OF BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1370\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1370|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/20/12610\" title=\"figure 1\">",
"      Tissue factor and coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/51/32574\" title=\"figure 2\">",
"      Coagulation cascade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/16/36110\" title=\"figure 3\">",
"      Mechanisms of action of heparin LMW heparin and fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1370|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/0/24590\" title=\"table 1\">",
"      Dabigatran drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/29/12766\" title=\"table 2\">",
"      Rivaroxaban drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/56/8078\" title=\"table 3\">",
"      Apixaban drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/11/14515?source=related_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_59_37819="Ann Arbor system in lymphoma";
var content_f36_59_37819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ann Arbor staging classification for Hodgkin and non-Hodgkin lymphomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Stage I",
"       </td>",
"       <td>",
"        Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (IE)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Stage II",
"       </td>",
"       <td>",
"        Involvement of two or more lymph node regions or lymphatic structures on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (IIE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Stage III",
"       </td>",
"       <td>",
"        Involvement of lymph node regions on both sides of the diaphragm (III), which may include the spleen (IIIS) or limited, contiguous extralymphatic organ or site (IIIE) or both (IIIES)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Stage IV",
"       </td>",
"       <td>",
"        Diffuse or disseminated foci of involvement of one or more extralymphatic organs or tissues, with or without associated lymphatic involvement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All cases are subclassified to indicate the absence (A) or presence (B) of the",
"    <strong>",
"     systemic (\"B\") symptoms",
"    </strong>",
"    of significant unexplained fever (&gt;38 degrees C), night sweats, or unexplained weight loss exceeding 10 percent of body weight during the six months prior to diagnosis. Clinical stage refers to the extent of disease determined by diagnostic tests following a single diagnostic biopsy. If a second biopsy of any kind is obtained, even if negative, the term pathologic stage is used.",
"    <div class=\"footnotes\">",
"     * The designation \"E\" generally refers to",
"     <strong>",
"      extranodal contiguous extension",
"     </strong>",
"     (ie, proximal or contiguous extranodal disease) that can be encompassed within an irradiation field appropriate for nodal disease of the same anatomic extent. A single extralymphatic site as the",
"     <strong>",
"      only site of disease",
"     </strong>",
"     should be classified as IE, rather than stage IV.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Carbone PP, et al. Cancer Res 1971; 31:1860 and Lister TA, et al. J Clin Oncol 1989; 7:1630.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37819=[""].join("\n");
var outline_f36_59_37819=null;
var title_f36_59_37820="Immature brain sz suscept";
var content_f36_59_37820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors promoting increased seizure susceptibility in the developing brain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Consequence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Input resistance and time constant: Increased in immature neurons",
"       </td>",
"       <td>",
"        Small inputs result in relatively large voltage changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voltage-gated ion channels: Earlier maturation of sodium and calcium channels, delayed development of potassium channels",
"       </td>",
"       <td>",
"        Longer action potentials, shorter refractory periods, increased neuron firing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synapse development: Excitatory synapses appear before inhibitory synapses",
"       </td>",
"       <td>",
"        Relative predominance of excitation over inhibition early in development",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synapse development: Over expression of excitatory synapses during critical period",
"       </td>",
"       <td>",
"        Corresponds to window of heightened seizure susceptibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developmental changes in glutamate receptor subunits: NR2B/NR2A ratio favors prolonged depolarizing responses; NR2D relative over expression reduces Mg",
"        <sup>",
"         ++",
"        </sup>",
"        block",
"       </td>",
"       <td>",
"        Favor relative hyperexcitability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Late appearance of functional inhibitory synapses",
"       </td>",
"       <td>",
"        Along with other factors favoring excitation, contributes to neuronal excitatory drive and lack of functional inhibition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developmental changes in GABA",
"        <sub>",
"         A",
"        </sub>",
"        receptor function and Cl",
"        <sup>",
"         -",
"        </sup>",
"        gradient",
"       </td>",
"       <td>",
"        GABA is depolarizing early in life, enhancing excitability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developmental changes in GABA",
"        <sub>",
"         A",
"        </sub>",
"        receptor subunits",
"       </td>",
"       <td>",
"        Partially accounts for developmental differences in inhibitory effectiveness and benzodiazepine responsiveness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developmental sensitivity to glutamate toxicity",
"       </td>",
"       <td>",
"        Less glutamate-induced excitotoxicity early in development",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immature GABA",
"        <sub>",
"         A",
"        </sub>",
"        binding pattern in substantia nigra",
"       </td>",
"       <td>",
"        Proconvulsant effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrical synapses: More common early in development",
"       </td>",
"       <td>",
"        Mechanism for enhanced synchrony of neuronal networks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immature homeostatic mechanisms: NaK-ATPase, glial K",
"        <sup>",
"         +",
"        </sup>",
"        regulation, K",
"        <sup>",
"         +",
"        </sup>",
"        /Cl",
"        <sup>",
"         -",
"        </sup>",
"        co-transporter",
"       </td>",
"       <td>",
"        Prolonged exposure to elevated extracellular K",
"        <sup>",
"         +",
"        </sup>",
"        leads to further neuronal depolarization",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rho, JM, Stafstrom, CE. Neurophysiology of epilepsy. In: Pediatric Neurology: Principles and Practice, 4th ed, Swaiman, KF, Ashwal, S, Ferreiro, DM (Eds). Mosby Elsevier. Philadelphia 2006. Copyright &copy;2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37820=[""].join("\n");
var outline_f36_59_37820=null;
var title_f36_59_37821="Hemodynamic changes in normal pregnancy";
var content_f36_59_37821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemodynamic changes in normal pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal pregnancy is characterized by an increase in cardiac output, a reduction in systemic vascular resistance, and a modest decline in mean blood pressure. These changes are associated with a 10 to 15 beat/min increase in heart rate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37821=[""].join("\n");
var outline_f36_59_37821=null;
var title_f36_59_37822="QT dispersion patient groups";
var content_f36_59_37822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Mean QT dispersion in various patient groups",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 292px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A summary of many studies shows that the mean QT dispersion is very variable within each patient group and there is much overlap in values between groups.",
"    <div class=\"footnotes\">",
"     MI: myocardial infarction; LVH: left ventricular hypertrophy; HF: heart failure; DCM: dilated cardiomyopathy; HCM: hypertrophic cardiomyopathy; AMI: acute myocardial infarction; LQTS: long QT syndrome.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37822=[""].join("\n");
var outline_f36_59_37822=null;
var title_f36_59_37823="Echogenic bowel down synd";
var content_f36_59_37823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echogenic bowel, Down syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this transverse image at the level of the umbilical cord insertion, the bowel is diffusely echogenic. At very low gain settings, the bowel is as echogenic as bone. Amniocentesis revealed fetal Down syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Chasen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_59_37823=[""].join("\n");
var outline_f36_59_37823=null;
